Medizin
Refine
Year of publication
- 2016 (316) (remove)
Document Type
- Article (282)
- Doctoral Thesis (14)
- Part of Periodical (11)
- Book (4)
- Contribution to a Periodical (3)
- Conference Proceeding (1)
- Preprint (1)
Has Fulltext
- yes (316) (remove)
Is part of the Bibliography
- no (316) (remove)
Keywords
- Mitochondria (4)
- apoptosis (4)
- Apoptosis (3)
- Cancer (3)
- HIV (3)
- ROS (3)
- autophagy (3)
- cirrhosis (3)
- ABCB1 (2)
- Aging (2)
- Angiogenesis (2)
- B-cell lymphoma (2)
- Borrelia (2)
- Calcium (2)
- Cell signalling (2)
- Cortex (2)
- CyberKnife robotic radiosurgery (2)
- Diabetes mellitus (2)
- Diagnostic markers (2)
- Exercise (2)
- Experimental models of disease (2)
- Gender (2)
- Heart transplantation (2)
- Immunotherapy (2)
- Infection (2)
- NADPH oxidase (2)
- Pain (2)
- Patient blood management (2)
- Pneumonia (2)
- Proteomics (2)
- Stereotactic body radiation therapy (2)
- Structural plasticity (2)
- VEGF (2)
- atrial fibrillation (2)
- breast cancer (2)
- cancer (2)
- caspase-8 (2)
- complementary and alternative medicine (2)
- development (2)
- diagnosis (2)
- glioblastoma (2)
- hepatitis C (2)
- human (2)
- liver transplantation (2)
- mitosis (2)
- particulate matter (2)
- renal cell carcinoma (2)
- surgery (2)
- ubiquitination (2)
- A/D transition (1)
- ABS (1)
- AGC kinase (1)
- AIH immunopathogenesis (1)
- AJAP1 (1)
- APMPPE - acute posterior multifocal placoid pigment epitheliopathy (1)
- APP (1)
- ARDS (1)
- Abdominal infections (1)
- Academic medicine (1)
- Access (1)
- Acute calcolous cholecystitis (1)
- Acute leukemia (1)
- Acute myeloid leukemia (1)
- Adherence junctions (1)
- Adolescents (1)
- Adverse events (1)
- Air traffic (1)
- All-trans retinoic acid (1)
- Allergic asthma (1)
- Allogeneic hematopoietic stem (1)
- Allogeneic stem cell transplantation (1)
- Ameloblastoma (1)
- Anaemia (1)
- Anatomy (1)
- Anemia (1)
- Anti platelet therapy (1)
- Anti-tumor immunity (1)
- Antibiotic (1)
- Antibiotic stewardship (1)
- Anticoagulation (1)
- Antimicrobial resistance (1)
- Antivenom (1)
- Arrhythmia/all (1)
- Ascites (1)
- Aspergillus fumigatus (1)
- Atherosclerosis (1)
- Atrial fibrillation (1)
- Atxn2 (1)
- Aurora (1)
- Autologous stem cell transplantation (1)
- Automated Tube Potential Selection (1)
- Automatic Environmental Tobacco Smoke Emitter (1)
- Autophagy (1)
- Azan trichrome stain (1)
- B-cell non-Hodgkin lymphoma (1)
- BMC (1)
- Backpropagating action potential (1)
- Bacterial infection (1)
- Bacterial pathogenesis (1)
- Bariatric surgery (1)
- Beatmung (1)
- Becton Dickinson (1)
- Benefit (1)
- Bibliometric analysis (1)
- Biliary tree stones (1)
- Bisphosphonates (1)
- Blood loss (1)
- Blood transfusion (1)
- Bone defect (1)
- Bone regeneration (1)
- Brain injury (1)
- Breast cancer (1)
- Breech delivery (1)
- Bungarus niger (1)
- C. elegans (1)
- CA1 (1)
- CD95/Fas receptor (1)
- CDK inhibitor (1)
- CIK cells (1)
- CNS cancer (1)
- COPD (1)
- CRISPR/Cas9 (1)
- CT pulmonary angiography (1)
- CT radiation exposure (1)
- CUELA (1)
- CYBA/p22phox (1)
- CYP1A1 (1)
- Cancer Staging (1)
- Cancer detection (1)
- Capecitabine (1)
- Carbapenem-resistente Gram-negative Bakterien (CRGN) (1)
- Carbapenemasen (1)
- Cardiac (1)
- Cardiac output (1)
- Cardiology (1)
- Cardiomyocyte signaling pathways (1)
- Cardioprotection (1)
- Cardiovascular disease (1)
- Catch-up validation study (1)
- Catheter ablation (1)
- Cats (1)
- Cdk1/cyclin B1 (1)
- Celiac disease (1)
- Cell salvage (1)
- Cell therapy (1)
- Cerebellum (1)
- Cerebral cortex (1)
- Cesarean delivery (1)
- Checkpoint inhibitor (1)
- Chemical modification (1)
- Chemiluminescence (1)
- Chemorefractory advanced gastric cancer (1)
- Chemotherapy (1)
- Children (1)
- Chimerism (1)
- Cholecystectomy (1)
- Chondral Lesion (1)
- Chorion (1)
- Chronic hepatitis (1)
- Chronic inflammation (1)
- Cigarettes (1)
- Claudin 5 (1)
- Clinical competence (1)
- Clinical genetics (1)
- Clinical skills (1)
- Clinical trial (1)
- Clinical trials (1)
- Clonidine (1)
- Clustering (1)
- Cofilin (1)
- Collagen antibody-induced arthritis (1)
- Comorbidities (1)
- Compartmental modeling (1)
- Complementary medicine (1)
- Complex I (1)
- Compliance (1)
- Computed tomography pulmonary angiography (CTPA) (1)
- Computer simulation (1)
- Conduct disorder (1)
- Congenital ocular motor apraxia (1)
- Conventional Chemotherapeutic (1)
- Cord blood transplantation (1)
- Costs (1)
- Couch tracking (1)
- Craniomandibular disorders (1)
- Critical haematocrit (1)
- Croatia (1)
- Cross-contamination (1)
- Cryo-electron microscopy (1)
- Cryoballoon (1)
- Cytotoxic CD8+ T cell (1)
- DKK1 (1)
- DNA damage (1)
- DNA methylation (1)
- DNA replication (1)
- DNA-protein crosslinks (1)
- Daptomycin (1)
- Databases (1)
- Decision making (1)
- Decision trees (1)
- Decision-making (1)
- Decolonization (1)
- Delegation (1)
- Delivery mode (1)
- Delivery quality assurance (1)
- Dendritic spines (1)
- Denosumab (1)
- Density equalizing (1)
- Density equalizing mapping (1)
- Dentistry (1)
- Desinfektion von Flugzeugen (1)
- Desmin (1)
- Diagnosis (1)
- Digital breast tomosynthesis (DBT) (1)
- Digital mammography (1)
- Disinfection of aircraft (1)
- Distribution (1)
- Dogs (1)
- Domestic (1)
- Drug targeting (1)
- Drug therapy (1)
- Dual-Source CT (1)
- Dvc1 (1)
- E-learning (1)
- E. coli (1)
- EQ (1)
- EQ-5D (1)
- ET (1)
- Early goal-directed therapy (1)
- Echocardiography (1)
- Eclampsia (1)
- Economic evaluation (1)
- Economic impact (1)
- Electron transport chain (1)
- Electrotonic analysis (1)
- Elimination (1)
- Emotion regulation (1)
- Emphysema (1)
- Employment effect (1)
- Endometriosis (1)
- Endoscopic ultrasound (1)
- Endothelial permeability (1)
- Entorhinal cortex lesion (1)
- EnvZ signalling (1)
- Envenomation (1)
- Epidermolysis bullosa simplex with muscular dystrophy (1)
- Eradication (1)
- Erythema migrans (1)
- Erythrocytes (1)
- Europe (1)
- Evaluation (1)
- Everolimus (1)
- Evidence-based medicine (1)
- Ewing sarcoma (1)
- Excitability (1)
- Exercise Metabolism (1)
- Extracellular RNA (eRNA) (1)
- FOLFIRI (1)
- Fc receptor (1)
- Feedback (1)
- Females (1)
- Fetal bovine serum (1)
- Fibrosis (1)
- First-line combination antiretroviral therapy (1)
- Fleas (1)
- Flexible Endoscopic Evaluation of Swallowing (1)
- Folic acid (1)
- Follow-up (1)
- Functional capacity (1)
- Functional clustering (1)
- GSK2334470 (1)
- GVHD (1)
- Gallbladder percutaneous drainage (1)
- Gastritis (1)
- Gastrointestinal bleeding (1)
- Gastrointestinal neoplasm (1)
- Gender analysis (1)
- Gene expression (1)
- General clinical cardiology (1)
- General practice/family medicine (1)
- Genetics research (1)
- Germany (1)
- Gestational diabetes (1)
- Gimbaled tracking (1)
- Gram-positive infection (1)
- Granule cell (1)
- Gross tumor volume optimization (1)
- Growth cone (1)
- Guideline (1)
- Guidelines (1)
- H3 receptor (1)
- HMA (1)
- Hausarztpraxis (1)
- Health care workers (1)
- Heart regeneration (1)
- Hemodilution (1)
- Hemodynamic management (1)
- Hemostasis (1)
- Hepatitis C virus (1)
- Hepatitis c (1)
- Herd immunity (1)
- High-dose chemotherapy (1)
- Highly infectious diseases (1)
- Hochansteckende Krankheiten (1)
- Hodgkin lymphoma (1)
- Hodgkin-Lymphom (1)
- Homeostasis (1)
- Homeostatic plasticity (1)
- Homocysteine (1)
- Hospital (1)
- Hospitals (1)
- Household contacts (1)
- Hrvaška (1)
- Human behaviour (1)
- Human physiology (1)
- Humans (1)
- IAP proteins (1)
- IGRA (1)
- IL-11 (1)
- IL-13 (1)
- IL-22 (1)
- IL-6 (1)
- Immobilization (1)
- Immune response (1)
- Immunity (1)
- Immunocompromised (1)
- Immunology and Microbiology Section (1)
- Immunosuppressive agents (1)
- Immunosuppressive therapy (1)
- In vitro (1)
- In vivo (1)
- Incidence (1)
- Individualized intervention (1)
- Indoor air pollution (1)
- Induced pluripotent stem cells (1)
- Infant (1)
- Inflow obstruction (1)
- Influenza (1)
- Intensive care (1)
- Intensive care unit (1)
- Interdisciplinarity (1)
- Intermediate filaments (1)
- Intratumoral (1)
- Iron deficiency anemia (1)
- Ischemia/reperfusion injury (1)
- Ischemia–reperfusion injury (1)
- Itpr1 (1)
- Jaw (1)
- Joint destruction (1)
- Joubert syndrome (1)
- Kidney transplantation (1)
- Kiefer (1)
- Kim-1 (1)
- Kinases (1)
- Kinematic posture analysis (1)
- Krait (1)
- Kraniomandibuläre Dysfunktion (1)
- LC3B (1)
- LDL-cholesterol (1)
- LOS (1)
- LTBI (1)
- Lactation (1)
- Learning outcomes (1)
- Lecture (1)
- Left ventricular assist device (1)
- Left ventricular non-compaction, (1)
- Lenalidomide (1)
- Length of stay (1)
- Lice (1)
- Lineage tracing (1)
- Lipid metabolism (1)
- Lipid signaling (1)
- Lipid signalling (1)
- Liquid filled MicroLion ion chamber array (1)
- Liver cirrhosis (1)
- Liver metastases (1)
- Long-term care (1)
- Longitudinal (1)
- Low back pain (1)
- Ltbp4 (1)
- Lucigenin (1)
- Luftverkehr (1)
- Lungenkontusion (1)
- Lyme borreliosis (1)
- Lyme disease (1)
- Lyme disease - Borreliosis (1)
- MEDIC (1)
- MLC tracking (1)
- MLL-rearranged leukemia (1)
- MMF (1)
- MPA (1)
- MPN (1)
- MPN-U (1)
- MR-based histology (1)
- MRI (1)
- MRSA (1)
- Machine-learning (1)
- Macrophage Transdifferentiation (1)
- Magnetic resonance (1)
- Major bleeding (1)
- Major infection after cardiac surgery (1)
- Mammary gland (1)
- Manufacturing (1)
- Mapping (1)
- Measles (1)
- Medizinische Fachangestellte (1)
- Meldepflicht (1)
- Membrane assays (1)
- Mental health (1)
- Mesenchymal stem/stromal cells (1)
- Metabolic diseases (1)
- Metastatic breast cancer (1)
- Methicillin resistance (1)
- MicroRNAs (miRNAs) (1)
- Migrants (1)
- Minimal residual disease (1)
- Mitochondrial complex I (1)
- Modified FDI criteria (1)
- Molar tooth sign (1)
- Molecular biology (1)
- Monacolin K (1)
- Morphological modeling (1)
- Mortality (1)
- Motor control (1)
- Multi-resistant pathogens (1)
- Multidetector Computed Tomography (1)
- Multimodal imaging (1)
- Multiple myeloma (1)
- Multiple sclerosis (1)
- Multivariate analysis (1)
- Muscarinic acetylcholine receptor (1)
- Muscular diseases (1)
- Musculoskeletal system (1)
- Muskuloskeletales System (1)
- NADH:ubiquinone oxidoreductase (1)
- NHE (1)
- NK cell (1)
- NK cell subset (1)
- NO (1)
- NS3 protease inhibitor (1)
- NSF (1)
- NXF1 (1)
- Nackenmuskulatur (1)
- Neck muscles (1)
- Neoplasms (1)
- Nerve regeneration (1)
- Nervous system diseases (1)
- Neurodegeneration (1)
- Neuroinflammation (1)
- Neurotoxicity (1)
- Nitric oxide (1)
- Non-RCT (1)
- Non-alcoholic fatty liver disease (1)
- Non-coding RNAs (1)
- Non-neuronal cholinergic system (1)
- Nonsteroidal anti-inflammatory drugs (1)
- Nox (1)
- Nox4 (1)
- Nrf2 (1)
- Nucleophosmin-1 (1)
- OECD performance standards (1)
- OPRM1 methylation (1)
- OSCE (1)
- Olfactory system (1)
- Oncolytic adenovirus (1)
- Open source concept (1)
- Oppositional defiant disorder (1)
- Organ motion (1)
- Osmosensing (1)
- Osteoporosis (1)
- Ovarian cancer (1)
- Oxygen consumption (1)
- PAR (1)
- PDK1 (1)
- PELICAN (1)
- PIF pocket (1)
- PMF (1)
- PV (1)
- Parainfluenza (1)
- Parkinson's disease (1)
- Particulate matter (1)
- Patellofemoral Joint (1)
- Pathogen reduction (1)
- Pdgfrβ (1)
- Peer-feedback (1)
- Peer-teaching (1)
- Pegylated liposomal doxorubicin (1)
- Persistence (1)
- Pharmacological treatment (1)
- Pharmacology (1)
- Phosphorylation (1)
- Physicians (1)
- Placental growth factor (1)
- Platelet (1)
- Platelet lysate (1)
- Platelet releasate (1)
- Plectin (1)
- Plk1 inhibitors (1)
- Polo-like kinase 3 (1)
- Polyhexanide (1)
- Population-based screening (1)
- Porin regulation (1)
- Post-translational modifications (1)
- Pre-economic effects (1)
- Pre-emptive immunotherapy (1)
- Pre-treatment drug resistance mutations (1)
- Preclinical research (1)
- Predictive medicine (1)
- Preeclampsia (1)
- Pregnancy (1)
- Primary care (1)
- Primärversorgung (1)
- Produkte zur Desinfektion (1)
- Progranulin (1)
- Protein aggregates (1)
- Proximal humeral fracture (1)
- Pseudo HE-images (1)
- Pulse contour analysis (1)
- Pulse pressure variation (1)
- Qualifikation (1)
- Quality of care (1)
- Quantitative MRI (1)
- RCT (1)
- RIPK3 (1)
- ROS generation (1)
- RT-qPCR (1)
- Radiofrequency (1)
- Raman spectroscopy (1)
- Randomised controlled trial (1)
- Randomized controlled trial (1)
- Rational use (1)
- Reactive oxygen species (1)
- Recall rate (1)
- Reconstructed human epidermis (1)
- Red blood cells (1)
- Red yeast rice (1)
- Redox (1)
- Regression analysis (1)
- Rehospitalization (1)
- Relapse (1)
- Relaxometry (1)
- Remote ischemic conditioning (1)
- Renal cell carcinoma (1)
- Renal function (1)
- Research architecture (1)
- Residential care (1)
- Resin composites (1)
- Respiration (1)
- Respiratory signs and symptoms (1)
- Respiratory syncytial virus (1)
- Rheumatoid arthritis (1)
- Robotic tracking (1)
- Roma women (1)
- Rora (1)
- Rotorest (1)
- Ruijs-Aalfs syndrome (1)
- Ryanodine (1)
- S. cerevisiae (1)
- SAP (1)
- SCT (1)
- SPARTAN (1)
- SPRTN (1)
- SR protein (1)
- SRSF3 (1)
- SRSF7 (1)
- STAT3 (1)
- STIR (1)
- SW480 Cell (1)
- Salmonella infection (1)
- Schmerz (1)
- Science structure (1)
- Scientometric analysis (1)
- Scientometrics (1)
- Sclerostin (1)
- Second stage of labor (1)
- Second-line treatment (1)
- Sensorimotor training (1)
- Sensory neuron (1)
- Sepsis-bundle (1)
- Sequence (1)
- Signaling (1)
- Signaling ROS (1)
- Skeletal muscle (1)
- Skeletal muscle fiber-type switching (1)
- Skills training (1)
- Skin irritation test (1)
- Skin manifestation (1)
- Smac (1)
- Smooth muscle cell (1)
- Snakebite (1)
- Socioeconomic status (1)
- Software tool (1)
- Spectral library (1)
- Sphere Formation Assay (1)
- Splice variants (1)
- Standardized operating procedures (1)
- Standardverfahren (1)
- Stroke (1)
- Stroke prevention (1)
- Stroke volume variation (1)
- Substances for disinfection (1)
- Sulfhydryl-reactivity (1)
- Sulfur metabolism (1)
- Sunitinib (1)
- Superinfection (1)
- Superoxide (1)
- Surgery (1)
- Surgical risk (1)
- Surveillance (1)
- Sympathicolysis (1)
- Synaptic plasticity (1)
- Synaptopodin (1)
- Synovial inflammation (1)
- Systematic review (1)
- Systemic treatment (1)
- T cell/histiocyte rich large B cell lymphoma (1)
- T cells (1)
- T1 (1)
- T84 colon carcinoma cells (1)
- TAX1BP1 (1)
- TRAIL (1)
- Target identification (1)
- Targeted therapy (1)
- Tax effect (1)
- Tgfβ (1)
- Therapeutics (1)
- Thermodilution (1)
- Thermoplasma (1)
- Thiol redox modification (1)
- Thromboembolism (1)
- Thrombosis (1)
- Thrombosis/hypercoagulable states (1)
- Ticks (1)
- Topoisomerase (1)
- Transfusion (1)
- Translational research (1)
- Transmembrane communication (1)
- Transmission (1)
- Trauma (1)
- Travellers (1)
- Treatment (1)
- Treatment protocol (1)
- Tumor suppressor protein (1)
- Tumorsphere Formation (1)
- Tyrosine kinase inhibitor (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- Tyrosine kinases (1)
- USP9X (1)
- Undergraduate training (1)
- Upper respiratory tract infection (1)
- Urban (1)
- VE-cadherin (1)
- Vaccination (1)
- Vaginal breech delivery (1)
- Vaginal delivery (1)
- Value-added effect (1)
- Vascular permeability (1)
- Viral load (1)
- Virological failure (1)
- Voltage attenuation (1)
- WRNIP1 (1)
- XIAP (1)
- Zoonosis (1)
- acetaminophen (1)
- acute coronary syndrome (1)
- acute liver injury (1)
- acute myeloid leukemia (AML) (1)
- adalimumab (1)
- adenomatous polyposis (1)
- adenosine (1)
- adhesion (1)
- adipose tissue-derived stem cell (1)
- advance directive (1)
- advanced care planning (1)
- age-related macular degeneration (1)
- aging (1)
- allogeneic stem cell transplantation (1)
- allosteric regulation (1)
- alternative 3′ end processing (1)
- anal carcinoma (1)
- angiogenesis (1)
- angioplasty (1)
- angiopoietin-2 (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- animal host (1)
- animal models (1)
- antenatal characteristics (1)
- antenatalne značilnosti (1)
- anti-citrullinated protein antibodies (1)
- anticoagulants (1)
- anticonvulsant activity (1)
- antiviral (1)
- antiviral therapy (1)
- archaea (1)
- archaeosomes (1)
- artery (1)
- astrocytoma (1)
- asymmetric hearing (1)
- auditory development (1)
- autoantibodies (1)
- automatic environmental tobacco smoke emitter (1)
- behavior (1)
- binaural cochlear implants (1)
- bio-absorbable mesh (1)
- biochemistry (1)
- biological mesh (1)
- biomarker (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- brain metastases (1)
- brain states (1)
- brainmass (1)
- brainsize (1)
- bronchial allergen challenge (1)
- burden of illness (1)
- c1orf124 (1)
- cancer care (1)
- cancer care providers (1)
- cancer screening (1)
- candidate genes (1)
- carbapenem-resistant Gram-negative bacteria (CRGN) (1)
- carbapenemases (1)
- carboxyfluorescein (1)
- cardiovascular magnetic resonance (1)
- carotid (1)
- catheterization/diagnostic interventional (1)
- cell biology (1)
- cell death (1)
- cell transplantation (1)
- cells (1)
- central nervous system infection (1)
- chemokines: CYP2D6 model (1)
- chemoradiotherapy (1)
- chromosome segregation (1)
- chronic hepatitis C (1)
- chronic viral hepatitis (1)
- cigarette smoke (1)
- clusteranalysis (1)
- cochlear implant (1)
- cold tolerance (1)
- compaction (1)
- complement (1)
- compliance (1)
- connectional fingerprint (1)
- connective tissue (1)
- continuing education (1)
- cortical layers and areas (1)
- cross-modal plasticity (1)
- cytokine (1)
- cytokines (1)
- deaf white cat (1)
- deafness (1)
- decision making (1)
- dedifferentiation (1)
- dentate gyrus (1)
- dentist (1)
- depression (1)
- deprivation (1)
- desensitization (1)
- desmoplastic stroma (1)
- diclofenac (1)
- differentiation (1)
- diffuse large B cell lymphoma (1)
- diffusion MRI (1)
- diffusion tensor imaging (1)
- direct antiviral agents (1)
- drug resistance (1)
- eNOS (1)
- editorials (1)
- electrocardiography (1)
- endothelial (1)
- endothelial cells (1)
- endothelial receptor expression (1)
- environmental tobacco smoke (1)
- epilepsy (1)
- erosions (1)
- eutheria (1)
- exercise testing (1)
- exome sequencing (1)
- familial colorectal cancer (1)
- fasting (1)
- fear conditioning (1)
- fear generalization (1)
- fibrosarcoma (1)
- fracture (1)
- freeze avoidance (1)
- gadobutrol (1)
- gender (1)
- gene expression (1)
- gene expression profiling (1)
- gene expression profiling (GEP) (1)
- generic preparedness (1)
- glucocorticoids (1)
- gold nanoparticles (1)
- governance (1)
- graph theory (1)
- green fluorescent protein (1)
- guideline (1)
- health-related quality of life (1)
- hepatitis c (1)
- hepatocytes (1)
- hepatotoxicity (1)
- herb induced liver injury (HILI) (1)
- herbal drug (1)
- herbal hepatotoxicity (1)
- hereditary angioedema (1)
- hereditary tumor syndromes (1)
- high-dose chemotherapy (1)
- histamine (1)
- histological validation (1)
- homoarginine (1)
- hormones (1)
- host response (1)
- human brain (1)
- human gingival fibroblasts (1)
- human natural killer cell (1)
- hypoxia (1)
- iCLIP (1)
- immune evasion (1)
- immune reconstitution (1)
- immune response (1)
- immunocompromised patient (1)
- immunologic (1)
- immunostaining (1)
- in situ hybridization (1)
- in situ vaccine (1)
- incisional hernia (1)
- influenza pandemic (1)
- information needs (1)
- innate immunity (1)
- insertable cardiac monitor (1)
- interaural time difference (1)
- interferon (1)
- interferon-free antiviral treatment (1)
- invasion (1)
- irritable bowel syndrome (1)
- isomeric antagonists (1)
- kinase regulation (1)
- kinetische Therapie (1)
- laser (1)
- laser based cell manipulation (1)
- laser microdissection (1)
- leukocytes (1)
- life span (1)
- liposomes (1)
- living will (1)
- local control (1)
- low-dose imaging (1)
- lymphoma pathogenesis (1)
- l‐arginine:glycine amidinotransferase (1)
- mRNA export (1)
- macrophages (1)
- magnetic resonance imaging (1)
- mammals (1)
- management (1)
- mandatory reporting system (1)
- mantle cell lymphoma (1)
- massive parallel sequencing (1)
- maturation (1)
- medical history (1)
- menthol (1)
- men’s (1)
- meta-analysis (1)
- metabolism (1)
- metalloprotease (1)
- miRNA (1)
- microbiome (1)
- microwave ablation (1)
- mismatch repair (1)
- mitotic arrest (1)
- molecular dynamics (1)
- mouse (1)
- multi-drug resistance (1)
- multidrug-resistant Gram-negative bacteria (MRGN) (1)
- multiresistente Gram-negativen Stäbchenbakterien (MRGN) (1)
- neuroblastoma (1)
- neuroinformatics (1)
- neuromodulation (1)
- nodular lymphocyte predominant Hodgkin lymphoma (1)
- noise intervention measures (1)
- nonnucleoside polymerase inhibitor (1)
- non‑Hodgkin's lymphoma (1)
- nuclear hormone receptor (1)
- nursery schools (1)
- observational study (1)
- occupational health (1)
- occupational stress (1)
- oncology (1)
- oral enzyme combination (1)
- orthodontist (1)
- osteoarthritis (1)
- osteoporosis (1)
- osteoporosis treatment (1)
- oval split ring resonator (1)
- p21 phosphorylation (1)
- p21 stability (1)
- pandemic preparedness (1)
- patient’s desires (1)
- pattern (1)
- perforin (1)
- perfusion (1)
- perinatal HIV infection (1)
- periodontal diseases (1)
- periodontitis (1)
- peripheral blood stem cell transplant (1)
- pirinixic acid (1)
- pirinixic acid derivative (1)
- pixantrone (1)
- pol g (1)
- pollen allergy (1)
- polo-like kinase (1)
- polycystic kidney (1)
- post hoc study (1)
- prefrontal cortex (1)
- prevention (1)
- progenitor (1)
- progeria (1)
- prognosis (1)
- proliferation (1)
- prophylaxis (1)
- protein kinase (1)
- proximal tubule (1)
- psoriatic arthritis (1)
- public health. (1)
- radiological (1)
- randomized controlled trial (1)
- rat model (1)
- real-world data (1)
- renal impairment (1)
- retuximab (1)
- risk communication (1)
- rituximab (1)
- romske ženske (1)
- salvage therapy (1)
- schizophrenia (1)
- senescence (1)
- sensory deprivation (1)
- sex‑determining region Y-box 11 (1)
- signature (1)
- single‐photon emission (1)
- size of cigarettes (1)
- skin conductance (1)
- skin involvement (1)
- sleep (1)
- slow-wave rhythms (1)
- smac mimetic (1)
- small compounds (1)
- sound analyses (1)
- sphingolipid (1)
- spirochetes (1)
- stellate reticulum (1)
- stereoselectivity (1)
- stress (1)
- stress response (1)
- stroke prevention (1)
- sulforaphane (1)
- survey (1)
- systematic review (1)
- targeted therapy (1)
- teratoma (1)
- testosterone (1)
- tetraether lipid (1)
- theranostics (1)
- therapy at the end of life (1)
- tobacco taxation (1)
- tolerance (1)
- training (1)
- treatment (1)
- trophiclevel (1)
- tumor immune escape (1)
- ubiquitin (1)
- ubiquitin coat (1)
- ubiquitin-binding zinc finger (1)
- ultra-high field MRI (1)
- vascular endothelial growth factor (1)
- vertebrates (1)
- vessel density (1)
- virological failure (1)
- waking state (1)
- wax layer (1)
- western blotting (1)
- winter survival (1)
- work ability (1)
- working conditions (1)
- xenobiotics (1)
- xenophagy (1)
- young people (1)
- μ-opioid receptor regulation (1)
Institute
- Medizin (316)
- Präsidium (11)
- Biowissenschaften (8)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Biochemie und Chemie (5)
- Pharmazie (5)
- Sonderforschungsbereiche / Forschungskollegs (4)
- Georg-Speyer-Haus (3)
- MPI für Hirnforschung (3)
- Sportwissenschaften (3)
The ubiquitin-binding zinc finger (UBZ) is a type of zinc-coordinating β-β-α fold domain found mainly in proteins involved in DNA repair and transcriptional regulation. Here, we report the crystal structure of the UBZ domain of Y-family DNA polymerase (pol) η and the crystal structure of the complex between the UBZ domain of Werner helicase-interacting protein 1 (WRNIP1) and ubiquitin, crystallized using the GFP fusion technique. In contrast to the pol η UBZ, which has been proposed to bind ubiquitin via its C-terminal α-helix, ubiquitin binds to a novel surface of WRNIP1 UBZ composed of the first β-strand and the C-terminal α-helix. In addition, we report the structure of the tandem UBZ domains of Tax1-binding protein 1 (TAX1BP1) and show that the second UBZ of TAX1BP1 binds ubiquitin, presumably in a manner similar to that of WRNIP1 UBZ. We propose that UBZ domains can be divided into at least two different types in terms of the ubiquitin-binding surfaces: the pol η type and the WRNIP1 type.
Alterations in dendritic spine numbers are linked to deficits in learning and memory. While we previously revealed that postsynaptic plasticity-related gene 1 (PRG-1) controls lysophosphatidic acid (LPA) signaling at glutamatergic synapses via presynaptic LPA receptors, we now show that PRG-1 also affects spine density and synaptic plasticity in a cell-autonomous fashion via protein phosphatase 2A (PP2A)/β1-integrin activation. PRG-1 deficiency reduces spine numbers and β1-integrin activation, alters long-term potentiation (LTP), and impairs spatial memory. The intracellular PRG-1 C terminus interacts in an LPA-dependent fashion with PP2A, thus modulating its phosphatase activity at the postsynaptic density. This results in recruitment of adhesome components src, paxillin, and talin to lipid rafts and ultimately in activation of β1-integrins. Consistent with these findings, activation of PP2A with FTY720 rescues defects in spine density and LTP of PRG-1-deficient animals. These results disclose a mechanism by which bioactive lipid signaling via PRG-1 could affect synaptic plasticity and memory formation.
Bewegung und sportliche Aktivität fördern die Gesundheit des Organismus und senken das Risiko chronischer Krankheiten. Sie bewirken dabei eine Vielzahl von physiologischen und biochemischen Veränderungen in der Skelettmuskulatur, insbesondere Muskelfasertyp-Transformation, Änderungen des Muskelmetabolismus und der Angiogenese. Unter basalen Bedingungen spielen reactive oxygen species (ROS) eine essentielle Rolle für die normale Muskelfunktion. Die Sport-induzierte Produktion von ROS erweist sich als wichtige physiologische Funktion für die Regulierung der Muskelkraft und der Anpassungsreaktion der Muskelfasern auf das Training. Eine der wichtigsten Quellen von ROS im kardiovaskulären System sowie in der Skelettmuskulatur ist die Familie der NADPH-Oxidasen (Nox). Im Unterschied zu anderen NADPHOxidasen ist Nox4 konstitutiv aktiv und produziert Wasserstoffperoxid (H2O2), welches in diversen zellulären Signalkaskaden involviert ist. Gleichzeitig gibt es zahlreiche Hinweise, dass Nox4 über die ROS-Produktion an Sport-induzierten Anpassungsprozessen in Skelettmuskeln beteiligt ist. Vor diesem Hintergrund wurde die Hypothese aufgestellt, dass Nox4 die Sport-induzierte Transformation von langsam- zu schnellkontrahierenden Muskelfasern, die Änderungen des Muskelstoffwechsels sowie die Sport-induzierte und die retinale Angiogenese beeinflusst. Die Untersuchung der Sportinduzierten Fasertyptransformation zeigte, dass die relative Zusammensetzung der Muskelfasern in Nox4-Knockout- und Wildtyp-Mäusen sehr ähnlich und somit von Nox4 unabhängig war. Obwohl das Training die Expression von PGC1α und GLUT4 sowie die AMPK-Aktivierung steigerte, hatte Nox4 nur eine geringe, nicht konstitutive Auswirkung auf den Muskelmetabolismus. Außerdem zeigte die vorliegende Studie, dass Nox4 die Sport-induzierte Angiogenese fördert. Nox4 führte zu einer erhöhten Stretch- und Hypoxie-induzierten Expression von VEGF in Myoblasten, die aus C2C12-Zellen und Satellitenzellen differenziert wurden. Als Folge des Nox4-Knockouts wurde nicht nur eine Reduktion der VEGF-Expression, sondern auch eine Steigerung der Expression von Angiopoietin 1 (Ang1) nachgewiesen, welches die Sport-induzierte Angiogenese hemmte. Das Fehlen von Nox4 schützte außerdem vor der retinalen Neoangiogenese und trug zu einer schnelleren Heilung nach der Oxygen-inducedretinopathy (OIR) bei, indem das Netzwerk neuer Gefäße mittels Ang1 stabilisiert wurde. Somit führt Nox4 zur Sport- und Hypoxie-induzierten Angiogenese durch einen Doppelmechanismus der Induktion und Aufrechterhaltung der VEGF Expression und der Hemmung von Ang1.
Introduction: This study reports about antenatal characteristics of Roma minority population. The study was designed to investigate data about health behaviours known to be associated with reproductive outcomes of Roma women that have very good living conditions and relatively high resource availability.
Methods: A retrospective study included 204 Roma and 408 non-Roma hospitalised singleton births that occurred in the Maternity Ward of the General Hospital Virovitica in the period from 1991 to 2010. Data about women’s age, marital status, smoking, reproductive health (abortions, delivery), antenatal care, perinatal complications and gestational age were taken from hospital records and analysed.
Results: Roma women were averagely more than three years younger than non-Roma women, only 10.8% were married. Smoking was more frequent. The average number of births of Roma and non-Roma women was similar, averagely two children per woman. The rate of induced abortions in the Roma women was higher, while the frequency of spontaneous abortions was equal. Inadequate antenatal care of Roma women was associated with two times higher incidence of perinatal complications. A higher frequency of deliveries at home without professional assistance in Roma pregnancy resulted in lower perinatal outcomes. It was confirmed that Roma mothers give birth earlier (38+6 vs. 39+4 weeks) and have a higher incidence of premature births (9.3% vs. 2.2%).
Conclusions: In the comparison of antenatal parameters between the two researched groups, poorer prenatal outcomes in the Roma population were found, despite full integration and considerable improvement in living standards of this ethnic Roma population.
This post hoc analysis of a phase 3 trial explored the effect of pixantrone in patients (50 pixantrone, 47 comparator) with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL) confirmed by centralized histological review. Patients received 28-d cycles of 85 mg/m2 pixantrone dimaleate (equivalent to 50 mg/m2 in the approved formulation) on days 1, 8 and 15, or comparator. The population was subdivided according to previous rituximab use and whether they received the study treatment as 3rd or 4th line. Median number of cycles was 4 (range, 2–6) with pixantrone and 3 (2–6) with comparator. In 3rd or 4th line, pixantrone was associated with higher complete response (CR) (23·1% vs. 5·1% comparator, P = 0·047) and overall response rate (ORR, 43·6% vs. 12·8%, P = 0·005). In 3rd or 4th line with previous rituximab (20 pixantrone, 18 comparator), pixantrone produced better ORR (45·0% vs. 11·1%, P = 0·033), CR (30·0% vs. 5·6%, P = 0·093) and progression-free survival (median 5·4 vs. 2·8 months, hazard ratio 0·52, 95% confidence interval 0·26–1·04) than the comparator. Similar results were found in patients without previous rituximab. There were no unexpected safety issues. Pixantrone monotherapy is more effective than comparator in relapsed or refractory aggressive B-cell NHL in the 3rd or 4th line setting, independently of previous rituximab.
Stroke is a major public health issue worldwide. The prevalence of stroke in 2010 was 33 million, with 16.9 million people having a first stroke.1 Stroke was the second‐leading cause of death behind heart disease globally, accounting for over 10% of total deaths worldwide.
Stroke is a heterogeneous condition that can be due to rupture of a blood vessel (hemorrhagic) or to blockage of a vessel (ischemic). About 85% of strokes are ischemic in origin and these are often classified by mechanism. This should be distinguished from risk factors such as hypertension, diabetes, smoking, etc. Risk factors increase the risk of stroke but do not necessarily explain the mechanism of a particular stroke. About 25% of ischemic strokes have a radiographic appearance similar to that seen in patients with cardioembolic sources (such as atrial fibrillation [AF], prosthetic valves, valvular prolapse, or mitral valve regurgitation), but no embolic source is found. These "cryptogenic strokes" (CS; also called embolic strokes of undetermined source) pose a particular clinical challenge in that the optimal antithrombotic therapy to reduce recurrence is uncertain. Since there are currently no data to support long‐term oral anticoagulation (OAC) in CS, but also no specific trials that have addressed this question, guidelines recommend antiplatelet therapy. Identification of AF in these patients changes the most likely mechanism to cardioembolism, and thus changes the recommended antithrombotic therapy to OAC, which is extremely effective in preventing stroke in patients with AF.
This report is based on discussions held at The Diagnostics and Monitoring Stroke Focus Group, a meeting held on January 15 to 17, 2015. The meeting focused on CS as a healthcare issue, and the utility of extended cardiac monitoring for AF in patients with strokes of unknown origin. The objectives of the meeting were to review existing information on the subject, define areas where knowledge was lacking or limited, and discuss study designs by which information gaps might be filled.
Nosological delineation of congenital ocular motor apraxia type Cogan : an observational study
(2016)
Background: The nosological assignment of congenital ocular motor apraxia type Cogan (COMA) is still controversial. While regarded as a distinct entity by some authorities including the Online Mendelian Inheritance in Man catalog of genetic disorders, others consider COMA merely a clinical symptom.
Methods: We performed a retrospective multicenter data collection study with re-evaluation of clinical and neuroimaging data of 21 previously unreported patients (8 female, 13 male, ages ranging from 2 to 24 years) diagnosed as having COMA.
Results: Ocular motor apraxia (OMA) was recognized during the first year of life and confined to horizontal pursuit in all patients. OMA attenuated over the years in most cases, regressed completely in two siblings, and persisted unimproved in one individual. Accompanying clinical features included early onset ataxia in most patients and cognitive impairment with learning disability (n = 6) or intellectual disability (n = 4). Re-evaluation of MRI data sets revealed a hitherto unrecognized molar tooth sign diagnostic for Joubert syndrome in 11 patients, neuroimaging features of Poretti-Boltshauser syndrome in one case and cerebral malformation suspicious of a tubulinopathy in another subject. In the remainder, MRI showed vermian hypo-/dysplasia in 4 and no abnormalities in another 4 patients. There was a strong trend to more severe cognitive impairment in patients with Joubert syndrome compared to those with inconclusive MRI, but otherwise no significant difference in clinical phenotypes between these two groups.
Conclusions: Systematical renewed analysis of neuroimaging data resulted in a diagnostic reappraisal in the majority of patients with early-onset OMA in the cohort reported here. This finding poses a further challenge to the notion of COMA constituting a separate entity and underlines the need for an expert assessment of neuroimaging in children with COMA, especially if they show cognitive impairment.
Infectious diseases remain a remarkable health threat for humans and animals. In the past, the epidemiology, etiology and pathology of infectious agents affecting humans and animals have mostly been investigated in separate studies. However, it is evident, that combined approaches are needed to understand geographical distribution, transmission and infection biology of “zoonotic agents”. The genus Bartonella represents a congenial example of the synergistic benefits that can arise from such combined approaches: Bartonella spp. infect a broad variety of animals, are linked with a constantly increasing number of human diseases and are transmitted via arthropod vectors. As a result, the genus Bartonella is predestined to play a pivotal role in establishing a One Health concept combining veterinary and human medicine.
Ziel. Lokoregionäre Rezidive sind der Hauptgrund für ein Therapieversagen nach primärer multimodaler Behandlung von Plattenepithelkarzinomen der Kopf-Hals-Region (SCCHN). Wir verglichen die Effektivität und Toxizität von Cisplatin oder Cetuximab simultan zur Re-Bestrahlung (ReRT) bei inoperablen SCCHN-Rezidiven. Ein prognostischer Score sollte auf Grundlage verschiedener klinischer und pathologischer Faktoren etabliert werden.
Patienten und Methoden. 66 Patienten mit in vorbestrahlten Regionen rezidivierten SCCHN wurden von 2007 bis 2014 simultan mit Cetuximab (n=33) oder cisplatin-basierter Chemotherapie (n=33) re-bestrahlt. Die Toxizität wurde wöchentlich sowie bei jedem Nachsorgetermin erfasst. Klinische Untersuchung, Endoskopie, CT- oder MRT-Untersuchungen wurden zur Beurteilung des Therapieansprechens und der Krankheitskontrolle eingesetzt.
Ergebnisse. Nach einer mittleren Nachbeobachtungszeit von 18,3 Monaten betrug das 1-Jahres-Überleben (OS) für ReRT mit Cetuximab 44,4% und mit cisplatin-basierter Chemotherapie 45,5% (p=0.352). Die lokalen Kontollraten nach einem Jahr waren jeweils 46,4% und 54,2% (p=0.625); die Raten an Metastasenfreiheit 73,6% und 81% (p=0.842). Hämatologische Toxizität ≥ Grad 3 kam in der Cisplatin-Gruppe häufiger vor (p<0.001), dagegen trat Schmerz ≥ Grad 3 in der Cetuximab-Gruppe häufiger auf (p=0.034). Ein physiologischer Hb-Wert und ein längeres Intervall zwischen primärer RT und ReRT erwiesen sich als signifikante prognostische Faktoren für das OS (multivariat: p=0.003 und p=0.002). Die Rezidivlokalisation sowie das GTV zeigten keinen signifikanten Einfluss auf das OS in der multivariaten Analyse (p=0.160 und p=0.167). Ein auf Grundlage dieser Variablen konstruierter Prognose-Score (0 bis 4 Punkte) zeigte signifikante Überlebensunterschiede: 1-Jahres-OS für 0/1/2/3/4 Prognosepunkte: 10%, 38%, 76%, 80% und 100% (p<0.001).
Schlussfolgerung. Sowohl Cetuximab- als auch Cisplatin-basierte ReRT für SCCHN-Rezidive sind gut durchführbare und effektive Behandlungsoptionen mit vergleichbaren Ergebnissen bezüglich Tumorkontrolle und Überleben. Die akuten Nebenwirkungen könnten gering variieren. Unser Prognose-Score könnte zur Identifizierung der für ReRT geeigneten Patienten sowie zur Stratifizierung in künftigen klinischen Studien dienen.
Da HRS-Zellen im cHL nur eine Minderheit und CD4+ T-Zellen die Mehrheit im Begleitinfiltrat ausmachen, wurde innerhalb der vorliegenden Dissertation das Begleitinfiltrat und der Tumorzellgehalt von 24 HIV-assoziierten cHL-Fällen mit 15 HIV-negativen cHL-Fällen immunhistochemisch verglichen. Das reaktive Begleitinfiltrat im HIV-assoziierten cHL zeigte eine deutlich geringere Anzahl an CD4+ T-Zellen und einen höheren Gehalt an CD163+ Makrophagen als das HIV-negative cHL. Es konnte kein Unterschied in der Anzahl der CD30+ HRS-Zellen und S100+ dendritischen Zellen zwischen beiden Gruppen festgestellt werden. Mit Kokultur-Versuchen im Labor und darauf folgenden Zellausstrichen dieser Kokulturen konnte bestätigt werden, dass sich CD14+ Monozyten ebenso gut wie CD4+ T-Zellen als Rosetten um HRS-Zellen anordnen können. Im immunkomprimierten HIV-Patienten ersetzen die langlebigen CD163+ Makrophagen die CD4+ T-Zellen. Die Makrophagen werden vermutlich ebenso wie CD4+ T-Zellen mittels Zytokine/Chemokine (z. B. CCL5) zum Tumorgewebe rekrutiert, bilden Rosetten um die Tumorzellen und unterstützen diese in ihrer Proliferation.
Aufgrund der besonderen Zusammensetzung des Begleitinfiltrats sollte das HIV-assoziierte cHL von Pathologen als eigenständiger Subtyp des cHL betrachtet werden.
Des Weiteren wurde das Begleitinfiltrat der typisch knotigen NLPHL Typen A und C mit dem des diffusen NLPHL Typen E (THRLBCL-like NLPHL) und dem THRLBCL immunhistochemisch verglichen. Aufgrund histologischer und klinischer Ähnlichkeiten zwischen dem diffusen NLPHL und dem THRLBCL fällt eine Differenzierung dieser Entitäten schwer. Es konnte festgestellt werden, dass das Begleitinfiltrat im THRLBCL-like NLPHL dem Begleitinfiltrat im THRLBCL mehr ähnelt als dem typischen NLPHL und zwar in Bezug auf Makrophagengehalt und Anzahl der follikulären TFH-Zellen. Es konnten Rosetten im Begleitinfiltrat von THRLBCL nachgewiesen werden, obwohl Rosettenformationen um Tumorzellen im THRLBCL in der Literatur kein charakteristisches Merkmal darstellen. Es ist naheliegend, dass das THRLBCL-like NLPHL und das THRLBCL ein und dieselbe Krankheit ist und möglicherweise eine aggressivere Variante des NLPHL darstellt.
Im Anbetracht aller Ergebnisse kommt dem Immunstatus eines Patienten eine ausschlaggebende Rolle auf das Begleitinfiltrat im Tumorgewebe zu und dieser beeinflusst so auch den klinischen Verlauf der Lymphomerkrankung.
Background: Patients with Ph-negative myeloproliferative neoplasms (MPN), such as polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are at increased risk for thrombosis/thromboembolism and major bleeding. Due to the morbidity and mortality of these events, antiplatelet and/or anticoagulant agents are commonly employed as primary and/or secondary prophylaxis. On the other hand, disease-related bleeding complications (i.e., from esophageal varices) are common in patients with MPN. This analysis was performed to define the frequency of such events, identify risk factors, and assess antiplatelet/anticoagulant therapy in a cohort of patients with MPN.
Methods: The MPN registry of the Study Alliance Leukemia is a non-interventional prospective study including adult patients with an MPN according to WHO criteria (2008). For statistical analysis, descriptive methods and tests for significant differences as well as contingency tables were used to identify the odds of potential risk factors for vascular events.
Results: MPN subgroups significantly differed in sex distribution, age at diagnosis, blood counts, LDH levels, JAK2V617F positivity, and spleen size (length). While most thromboembolic events occurred around the time of MPN diagnosis, one third of these events occurred after that date. Splanchnic vein thrombosis was most frequent in post-PV-MF and MPN-U patients. The chance of developing a thromboembolic event was significantly elevated if patients suffered from post-PV-MF (OR 3.43; 95 % CI = 1.39–8.48) and splenomegaly (OR 1.76; 95 % CI = 1.15–2.71). Significant odds for major bleeding were previous thromboembolic events (OR = 2.71; 95 % CI = 1.36–5.40), splenomegaly (OR = 2.22; 95 % CI 1.01–4.89), and the administration of heparin (OR = 5.64; 95 % CI = 1.84–17.34). Major bleeding episodes were significantly less frequent in ET patients compared to other MPN subgroups.
Conclusions: Together, this report on an unselected "real-world" cohort of German MPN patients reveals important data on the prevalence, diagnosis, and treatment of thromboembolic and major bleeding complications of MPN.
In ∼30% of families affected by colorectal adenomatous polyposis, no germline mutations have been identified in the previously implicated genes APC, MUTYH, POLE, POLD1, and NTHL1, although a hereditary etiology is likely. To uncover further genes with high-penetrance causative mutations, we performed exome sequencing of leukocyte DNA from 102 unrelated individuals with unexplained adenomatous polyposis. We identified two unrelated individuals with differing compound-heterozygous loss-of-function (LoF) germline mutations in the mismatch-repair gene MSH3. The impact of the MSH3 mutations (c.1148delA, c.2319−1G>A, c.2760delC, and c.3001−2A>C) was indicated at the RNA and protein levels. Analysis of the diseased individuals’ tumor tissue demonstrated high microsatellite instability of di- and tetranucleotides (EMAST), and immunohistochemical staining illustrated a complete loss of nuclear MSH3 in normal and tumor tissue, confirming the LoF effect and causal relevance of the mutations. The pedigrees, genotypes, and frequency of MSH3 mutations in the general population are consistent with an autosomal-recessive mode of inheritance. Both index persons have an affected sibling carrying the same mutations. The tumor spectrum in these four persons comprised colorectal and duodenal adenomas, colorectal cancer, gastric cancer, and an early-onset astrocytoma. Additionally, we detected one unrelated individual with biallelic PMS2 germline mutations, representing constitutional mismatch-repair deficiency. Potentially causative variants in 14 more candidate genes identified in 26 other individuals require further workup. In the present study, we identified biallelic germline MSH3 mutations in individuals with a suspected hereditary tumor syndrome. Our data suggest that MSH3 mutations represent an additional recessive subtype of colorectal adenomatous polyposis.
For infectious diseases caused by highly pathogenic agents (e. g., Ebola/Lassa fever virus, SARS-/MERS-CoV, pandemic influenza virus) which have the potential to spread over several continents within only a few days, international Health Protection Authorities have taken appropriate measures to limit the consequences of a possible spread. A crucial point in this context is the disinfection of an aircraft that had a passenger on board who is suspected of being infected with one of the mentioned diseases. Although, basic advice on hygiene and sanitation on board an aircraft is given by the World Health Organization, these guidelines lack details on available and effective substances as well as standardized operating procedures (SOP). The purpose of this paper is to give guidance on the choice of substances that were tested by a laboratory of Lufthansa Technik and found compatible with aircraft components, as well as to describe procedures which ensure a safe and efficient disinfection of civil aircrafts. This guidance and the additional SOPs are made public and are available as mentioned in this paper.
Iron deficiency anemia (IDA) is associated with a number of pathological gastrointestinal conditions other than inflammatory bowel disease, and also with liver disorders. Different factors such as chronic bleeding, malabsorption and inflammation may contribute to IDA. Although patients with symptoms of anemia are frequently referred to gastroenterologists, the approach to diagnosis and selection of treatment as well as follow-up measures is not standardized and suboptimal. Iron deficiency, even without anemia, can substantially impact physical and cognitive function and reduce quality of life. Therefore, regular iron status assessment and awareness of the clinical consequences of impaired iron status are critical. While the range of options for treatment of IDA is increasing due to the availability of effective and well-tolerated parenteral iron preparations, a comprehensive overview of IDA and its therapy in patients with gastrointestinal conditions is currently lacking. Furthermore, definitions and assessment of iron status lack harmonization and there is a paucity of expert guidelines on this topic. This review summarizes current thinking concerning IDA as a common co-morbidity in specific gastrointestinal and liver disorders, and thus encourages a more unified treatment approach to anemia and iron deficiency, while offering gastroenterologists guidance on treatment options for IDA in everyday clinical practice.
Aims: History of bleeding strongly influences decisions for anticoagulation in atrial fibrillation (AF). We analyzed outcomes in relation to history of bleeding and randomization in ARISTOTLE trial patients.
Methods and results: The on-treatment safety population included 18,140 patients receiving at least 1 dose of study drug (apixaban) or warfarin. Centrally adjudicated outcomes in relation to bleeding history were analyzed using a Cox proportional hazards model adjusted for randomized treatment and established risk factors. Efficacy end points were analyzed on the randomized (intention to treat) population. A bleeding history was reported at baseline in 3,033 patients (16.7%), who more often were male, with a history of prior stroke/transient ischemic attack/systemic embolism and diabetes; higher CHADS2 scores, age, and body weight; and lower creatinine clearance and mean systolic blood pressure. Major (but not intracranial) bleeding occurred more frequently in patients with versus without a history of bleeding (adjusted hazard ratio 1.35, 95% CI 1.14-1.61). There were no significant interactions between bleeding history and treatment for stroke/systemic embolism, hemorrhagic stroke, death, or major bleeding, with fewer outcomes with apixaban versus warfarin for all of these outcomes independent of the presence/absence of a bleeding history.
Conclusion: In patients with AF in a randomized clinical trial of oral anticoagulants, a history of bleeding is associated with several risk factors for stroke and portends a higher risk of major—but not intracranial—bleeding, during anticoagulation. However, the beneficial effects of apixaban over warfarin for stroke, hemorrhagic stroke, death, or major bleeding remains consistent regardless of history of bleeding.
Ziel:
Vergleich der Veränderung der mütterlichen Einstellung zur Geburt anhand von Hebammen geführten Geburtsvorbereitungskursen oder hypnoreflexogenem Training zur Geburtsvorbereitung.
Methode:
Zu Beginn und nach Beendigung der Kurse wurde die mütterliche Einstellung zur Geburt unter Zuhilfenahme des Osgood-Ertel-Eindrucksdifferenzials gemessen. Der Gießen-Test zur Persönlichkeitsbeurteilung wurde einmalig angewendet.
Ergebnisse:
213 Frauen waren in die Studie eingeschlossen. 155 davon nahmen an, von Hebammen geführten, Geburtsvorbereitungskursen teil. 58 Frauen absolvierten ein hypnoreflexogenes Training. Es waren zu Beginn der Kurse keine statistisch signifikanten Unterschiede feststellbar in Bezug auf die Charakteristiken der Teilnehmerinnen sowie im Gießen-Test und in den Ergebnissen des Osgood-Ertel-Eindrucksdifferenzials. Nach der von Hebammen geführten Geburtsvorbereitung wurde die Geburt negativer wahrgenommen(Freudlosigkeit und Trübung in der Valenz-Dimension [p < 0,05]), während die Geburt nach dem Hypnosetraining emotional positiver bewertet wurde (Freude
und Harmonie in der Valenz-Dimension [p < 0,01] sowie Helligkeit [p < 0,05]).
Zusammenfassung:
Hypnoreflexogenes Selbsthypnosetraining zur Geburtsvorbereitung scheint stärkere und positivere mütterliche emotionale Veränderungen in Bezug auf die
Einstellung zur Geburt auszulösen als konventionelle, von Hebammen geführte Geburtsvorbereitungskurse. Weitere retrospektive randomisierte Studien sind nötig, um diese Ergebnisse zu überprüfen.
Background: Despite novel therapeutic agents, most multiple myeloma (MM) patients eventually relapse. Two large phase III trials have shown significantly improved response rates (RR) of lenalidomide/dexamethasone compared with placebo/dexamethasone in relapsed MM (RMM) patients. These results have led to the approval of lenalidomide for RMM patients and lenalidomide/dexamethasone has since become a widely accepted second-line treatment. Furthermore, in RMM patients consolidation with high-dose chemotherapy plus autologous stem cell transplantation has been shown to significantly increase progression free survival (PFS) as compared to cyclophosphamide in a phase III trial. The randomized prospective ReLApsE trial is designed to evaluate PFS after lenalidomide/dexamethasone induction, high-dose chemotherapy consolidation plus autologous stem cell transplantation and lenalidomide maintenance compared with the well-established lenalidomide/dexamethasone regimen in RMM patients.
Methods/Design: ReLApsE is a randomized, open, multicenter phase III trial in a planned study population of 282 RMM patients. All patients receive three lenalidomide/dexamethasone cycles and - in absence of available stem cells from earlier harvesting - undergo peripheral blood stem cell mobilization and harvesting. Subsequently, patients in arm A continue on consecutive lenalidomide/dexamethasone cycles, patients in arm B undergo high dose chemotherapy plus autologous stem cell transplantation followed by lenalidomide maintenance until discontinuation criteria are met. Therapeutic response is evaluated after the 3rd (arm A + B) and the 5th lenalidomide/dexamethasone cycle (arm A) or 2 months after autologous stem cell transplantation (arm B) and every 3 months thereafter (arm A + B). After finishing the study treatment, patients are followed up for survival and subsequent myeloma therapies. The expected trial duration is 6.25 years from first patient in to last patient out. The primary endpoint is PFS, secondary endpoints include overall survival (OS), RR, time to best response and the influence of early versus late salvage high dose chemotherapy plus autologous stem cell transplantation on OS.
Discussion: This phase III trial is designed to evaluate whether high dose chemotherapy plus autologous stem cell transplantation and lenalidomide maintenance after lenalidomide/dexamethasone induction improves PFS compared with the well-established continued lenalidomide/dexamethasone regimen in RMM patients. Trial registration: ISRCTN16345835 (date of registration 2010-08-24).
Background: The quantification of global DNA methylation has been established in epigenetic screening. As more practicable alternatives to the HPLC-based gold standard, the methylation analysis of CpG islands in repeatable elements (LINE-1) and the luminometric methylation assay (LUMA) of overall 5-methylcytosine content in “CCGG” recognition sites are most widely used. Both methods are applied as virtually equivalent, despite the hints that their results only partly agree. This triggered the present agreement assessments.
Results: Three different human cell types (cultured MCF7 and SHSY5Y cell lines treated with different chemical modulators of DNA methylation and whole blood drawn from pain patients and healthy volunteers) were submitted to the global DNA methylation assays employing LINE-1 or LUMA-based pyrosequencing measurements. The agreement between the two bioassays was assessed using generally accepted approaches to the statistics for laboratory method comparison studies. Although global DNA methylation levels measured by the two methods correlated, five different lines of statistical evidence consistently rejected the assumption of complete agreement. Specifically, a bias was observed between the two methods. In addition, both the magnitude and direction of bias were tissue-dependent. Interassay differences could be grouped based on Bayesian statistics, and these groups allowed in turn to re-identify the originating tissue.
Conclusions: Although providing partly correlated measurements of DNA methylation, interchangeability of the quantitative results obtained with LINE-1 and LUMA was jeopardized by a consistent bias between the results. Moreover, the present analyses strongly indicate a tissue specificity of the differences between the two methods.
The use of fetal bovine serum (FBS) as a cell culture supplement is discouraged by regulatory authorities to limit the risk of zoonoses and xenogeneic immune reactions in the transplanted host. Additionally, FBS production came under scrutiny due to animal welfare concerns. Platelet derivatives have been proposed as FBS substitutes for the ex-vivo expansion of mesenchymal stem/stromal cells (MSCs) since platelet-derived growth factors can promote MSC ex-vivo expansion. Platelet-derived growth factors are present in platelet lysate (PL) obtained after repeated freezing-thawing cycles of the platelet-rich plasma or by applying physiological stimuli such as thrombin or CaCl2.PL-expanded MSCs have been used already in the clinic, taking advantage of their faster proliferation compared with FBS-expanded preparations. Should PL be applied to other biopharmaceutical products, its demand is likely to increase dramatically. The use of fresh platelet units for the production of PL raises concerns due to limited availability of platelet donors. Expired units might represent an alternative, but further data are needed to define safety, including pathogen reduction, and functionality of the obtained PL. In addition, relevant questions concerning the definition of PL release criteria, including concentration ranges of specific growth factors in PL batches for various clinical indications, also need to be addressed. We are still far from a common definition of PL and standardized PL manufacture due to our limited knowledge of the mechanisms that mediate PL-promoting cell growth. Here, we concisely discuss aspects of PL as MSC culture supplement as a preliminary step towards an agreed definition of the required characteristics of PL for the requirements of manufacturers and users.
Epigenetic signatures such as methylation of the monoamine oxidase A (MAOA) gene have been found to be altered in panic disorder (PD). Hypothesizing temporal plasticity of epigenetic processes as a mechanism of successful fear extinction, the present psychotherapy-epigenetic study for we believe the first time investigated MAOA methylation changes during the course of exposure-based cognitive behavioral therapy (CBT) in PD. MAOA methylation was compared between N=28 female Caucasian PD patients (discovery sample) and N=28 age- and sex-matched healthy controls via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells. MAOA methylation was furthermore analyzed at baseline (T0) and after a 6-week CBT (T1) in the discovery sample parallelized by a waiting time in healthy controls, as well as in an independent sample of female PD patients (N=20). Patients exhibited lower MAOA methylation than healthy controls (P<0.001), and baseline PD severity correlated negatively with MAOA methylation (P=0.01). In the discovery sample, MAOA methylation increased up to the level of healthy controls along with CBT response (number of panic attacks; T0–T1: +3.37±2.17%), while non-responders further decreased in methylation (−2.00±1.28%; P=0.001). In the replication sample, increases in MAOA methylation correlated with agoraphobic symptom reduction after CBT (P=0.02–0.03). The present results support previous evidence for MAOA hypomethylation as a PD risk marker and suggest reversibility of MAOA hypomethylation as a potential epigenetic correlate of response to CBT. The emerging notion of epigenetic signatures as a mechanism of action of psychotherapeutic interventions may promote epigenetic patterns as biomarkers of lasting extinction effects.
Background: Cell salvage is commonly used as part of a blood conservation strategy. However concerns among clinicians exist about the efficacy of transfusion of washed cell salvage.
Methods: We performed a meta-analysis of randomized controlled trials in which patients, scheduled for all types of surgery, were randomized to washed cell salvage or to a control group with no cell salvage. Data were independently extracted, risk ratio (RR), and weighted mean differences (WMD) with 95% confidence intervals (CIs) were calculated. Data were pooled using a random effects model. The primary endpoint was the number of patients exposed to allogeneic red blood cell (RBC) transfusion.
Results: Out of 1140 search results, a total of 47 trials were included. Overall, the use of washed cell salvage reduced the rate of exposure to allogeneic RBC transfusion by a relative 39% (RR = 0.61; 95% CI 0.57 to 0.65; P < 0.001), resulting in an average saving of 0.20 units of allogeneic RBC per patient (weighted mean differences [WMD] = -0.20; 95% CI -0.22 to -0.18; P < 0.001), reduced risk of infection by 28% (RR = 0.72; 95% CI 0.54 to 0.97; P = 0.03), reduced length of hospital stay by 2.31 days (WMD = -2.31; 95% CI -2.50 to -2.11; P < 0.001), but did not significantly affect risk of mortality (RR = 0.92; 95% CI 0.63 to 1.34; P = 0.66). No statistical difference could be observed in the number of patients exposed to re-operation, plasma, platelets, or rate of myocardial infarction and stroke.
Conclusions: Washed cell salvage is efficacious in reducing the need for allogeneic RBC transfusion and risk of infection in surgery.
Type I interferons (IFNs), including IFN-α, upregulate an array of IFN-stimulated genes (ISGs) and potently suppress Human immunodeficiency virus type 1 (HIV-1) infectivity in CD4(+) T cells, monocyte-derived macrophages, and dendritic cells. Recently, we and others identified ISG myxovirus resistance 2 (MX2) as an inhibitor of HIV-1 nuclear entry. However, additional antiviral blocks exist upstream of nuclear import, but the ISGs that suppress infection, e.g., prior to (or during) reverse transcription, remain to be defined. We show here that the HIV-1 CA mutations N74D and A105T, both of which allow escape from inhibition by MX2 and the truncated version of cleavage and polyadenylation specific factor 6 (CPSF6), as well as the cyclophilin A (CypA)-binding loop mutation P90A, all increase sensitivity to IFN-α-mediated inhibition. Using clustered regularly interspaced short palindromic repeat (CRISPR)/Cas9 technology, we demonstrate that the IFN-α hypersensitivity of these mutants in THP-1 cells is independent of MX2 or CPSF6. As expected, CypA depletion had no additional effect on the behavior of the P90A mutant but modestly increased the IFN-α sensitivity of wild-type virus. Interestingly, the infectivity of wild-type or P90A virus could be rescued from the MX2-independent IFN-α-induced blocks in THP-1 cells by treatment with cyclosporine (Cs) or its nonimmunosuppressive analogue SDZ-NIM811, indicating that Cs-sensitive host cell cyclophilins other than CypA contribute to the activity of IFN-α-induced blocks. We propose that cellular interactions with incoming HIV-1 capsids help shield the virus from recognition by antiviral effector mechanisms. Thus, the CA protein is a fulcrum for the dynamic interplay between cell-encoded functions that inhibit or promote HIV-1 infection.
Objective: ACPAs are associated with bone destruction in RA. The aim of this study was to evaluate the association between ACPA and bone destruction in patients with a distinct inflammatory disorder, PsA.
Methods: We used baseline data from a large observational study of PsA patients preparing to initiate treatment with adalimumab to analyse demographic and disease characteristics by ACPA status. To ensure a homogeneous PsA study population, only patients with active psoriatic skin manifestations who met Classification of Psoriatic Arthritis criteria for PsA were included in the analyses, thereby minimizing the risk of including misdiagnosed RA patients. Multiple logistic regression analyses were used to explore potential associations between ACPA seropositivity and bone destruction.
Results: Of 1996 PsA patients who met the strict inclusion criteria, 105 (5.3%) were positive for ACPA. ACPA-positive patients had significantly higher swollen joint counts and 28-joint DAS values than ACPA-negative patients and significantly higher rates of erosive changes and dactylitis. Multiple logistic regression analysis confirmed the association of ACPA seropositivity with a 2.8-fold increase in the risk of erosive disease.
Conclusion: As has been previously shown for RA, ACPA is associated with bone destruction in PsA, suggesting that the osteocatabolic effect of ACPA is not confined to RA but is also detectable in the different pathogenetic context of a distinct disease entity.
Trial registration: ClinicalTrials.gov, NCT01111240.
Der Nucleus suprachiasmaticus (SCN) ist ein Kerngebiet des Hypothalamus mit der Funktion des zentralen Taktgebers für die Generierung der circadianen Rhythmik. Zahlreiche petale Verbindungen zum SCN dienen der Synchronisierung der circadianen Uhr mit der tatsächlichen Tagesphase. Fugale Verbindungen des SCN dienen der Verteilung der Tageszeiteninformation über das Gehirn, insbesondere in vegetativen Zentren. So werden beispielsweise die physiologischen Vorgänge des Kreislaufsystems, Hormonausschüttung, der Schlaf-Wach-Zyklus etc. kontrolliert und mit Tag-Nacht-Wechsel synchronisiert. Obwohl viele dieser Verbindungen verstanden und beschrieben sind, sind die nahen Verbindungen in der unmittelbaren Nähe des SCN und des-sen intrinsische Verbindung nicht genau untersucht. Zur Darstellung dieser nahen Verbindungen wurden DiI-Tracer-Studien an Gehirnschnitten von Mäusen durchgeführt. Untersucht wurde parallel zu der DiI-Färbung das Neuropeptid Vasopressin innerhalb und außerhalb des SCN bei Mäusen von zwei verschiedenen Mäusestämmen (C3H und C57BL); C57BL ist defizient für das photoperiodische sezernierte Epiphysenhormon Melatonin, C3H-Mäuse er-blinden im frühen Lebensalter. Die immunzytochemische Untersuchung des Vasopressin-Systems belegte einen Unterschied in der Zytoarchitektur des SCN zwischen den C3H und C57BL Mäusen. Obwohl einige Elemente ähnliche Lokalisations- und Reaktivitätscharakteristika aufwiesen z.B. die dorsomediale Verteilung der Vasopressin-Perikaryen im Kerngebiet, so zeigte sich bei den C57BL-Mäusen eine deutlich schwächere Reaktivität des Neuropeptids AVP in diesem Bereich und ferner eine deutliche inhomogenere Verteilung der Vasopressin-Elemente im gesamten Kerngebiet. Die Tracing Untersuchung zeigte bei beiden Mäuse-Stämmen die gleichen Verbindungswege des SCN mit der nahen Periphere. Zum einen zeigen die Ergebnisse, dass der Hauptpassage des SCN im dorsomedialen, also im periventrikulären Bereich lokalisiert ist und das der SCN multiple Zugänge an seiner dorsalen und lateralen Grenze zur subparaventrikulären Zone besitzt. Ferner konnte auch gezeigt werden, dass beide bilateralen SCN-Kerne direkt über ausgeprägte Kommissurfaserverbindungen miteinander kommunizieren. Diese Kommissuren dürften dafür verantwortlich sein, den SCN einer Seite mit dem SCN der kontralateralen Seite zu synchronisieren. Obwohl in der vorliegenden Arbeit der Tracer nur einseitig appliziert wurde, ist dennoch von einer gekreuzten kontralateralen Verbindung auszugehen. Hier liegen Ansätze für weitere Un-tersuchungen. Ein weiterer Aspekt der Untersuchungen zeigen Faserverbin-dungen in die Area hypothalamica lateralis (AHL), die eine wichtige Rolle in der Kontrolle der zentralen Nahrungsaufnahme besitzt. Diese Faserverbin-dungen haben ihren Ursprung im SCN bzw. Nucl. paraventricularis und dem Nucl. arcuatus. Diese Verbindungen dienen am ehesten der Modulation der zentralen Regulation der Nahrungsaufnahme und spielen daher eine besondere Rolle in der Krankheitsentstehung wie Adipositas, Diabetes und Herz-Kreislauf-Erkrankung bei gestörter circadianen Rhythmik. Neu ist der Befund einer beachtlichen Anzahl von suprachiasmaticopetalen Fasern aus der sub-paraventrikulären Zone. Diese könnten die Einbindung des limbischen Systems in die Modulation der inneren Uhr erklären, die darüber hinaus ursächlich für zahlreiche Pathologien sein könnten.
We have developed a new in vitro skin irritation test based on an open source reconstructed epidermis (OS-REp) with openly accessible protocols for tissue production and test performance. Due to structural, mechanistic and procedural similarity, a blinded catch-up validation study for skin irritation according to OECD Performance Standards (PS) was conducted in three laboratories to promote regulatory acceptance, with OS-REp models produced at a single production site only. While overall sensitivity and predictive capacity met the PS requirements, overall specificity was only 57%. A thorough analysis of the test results led to the assumption that some of the false-positive classifications could have been evoked by volatile skin-irritating chemicals tested in the same culture plate as the non-irritants falsely predicted as irritants. With GC/MS and biological approaches the cross-contamination effect was confirmed and the experimental set-up adapted accordingly. Retesting of the affected chemicals with the improved experimental set-up and otherwise identical protocol resulted in correct classifications as non-irritants. Taking these re-test results into account, 93% overall sensitivity, 70% specificity and 82% accuracy was achieved, which is in accordance with the OECD PS. A sufficient reliability of the method was indicated by a within-laboratory-reproducibility of 85–95% and a between-laboratory-reproducibility of 90%.
Purpose: High precision radiosurgery demands comprehensive delivery-quality-assurance techniques. The use of a liquid-filled ion-chamber-array for robotic-radiosurgery delivery-quality-assurance was investigated and validated using several test scenarios and routine patient plans.
Methods and material: Preliminary evaluation consisted of beam profile validation and analysis of source–detector-distance and beam-incidence-angle response dependence. The delivery-quality-assurance analysis is performed in four steps: (1) Array-to-plan registration, (2) Evaluation with standard Gamma-Index criteria (local-dose-difference ⩽ 2%, distance-to-agreement ⩽ 2 mm, pass-rate ⩾ 90%), (3) Dose profile alignment and dose distribution shift until maximum pass-rate is found, and (4) Final evaluation with 1 mm distance-to-agreement criterion. Test scenarios consisted of intended phantom misalignments, dose miscalibrations, and undelivered Monitor Units. Preliminary method validation was performed on 55 clinical plans in five institutions.
Results: The 1000SRS profile measurements showed sufficient agreement compared with a microDiamond detector for all collimator sizes. The relative response changes can be up to 2.2% per 10 cm source–detector-distance change, but remains within 1% for the clinically relevant source–detector-distance range. Planned and measured dose under different beam-incidence-angles showed deviations below 1% for angles between 0° and 80°. Small-intended errors were detected by 1 mm distance-to-agreement criterion while 2 mm criteria failed to reveal some of these deviations. All analyzed delivery-quality-assurance clinical patient plans were within our tight tolerance criteria.
Conclusion: We demonstrated that a high-resolution liquid-filled ion-chamber-array can be suitable for robotic radiosurgery delivery-quality-assurance and that small errors can be detected with tight distance-to-agreement criterion. Further improvement may come from beam specific correction for incidence angle and source–detector-distance response.
Chronic hepatitis C is a major reason for development of cirrhosis and hepatocellular carcinoma and a leading cause for liver transplantation. The development of direct-acting antiviral agents lead to (pegylated) interferon-alfa free antiviral therapy regimens with a remarkable increase in sustained virologic response (SVR) rates and opened therapeutic options for patients with advanced cirrhosis and liver graft recipients. This concise review gives an overview about most current prospective trials and cohort analyses for treatment of patients with liver cirrhosis and liver graft recipients. In patients with compensated cirrhosis Child-Pugh-Turcotte (CTP) class A, all approved agents are safe and SVR rates do not significantly differ from patients without cirrhosis in general. In patients with decompensated cirrhosis CTP class B or C, daclastasvir, ledipasvir, velpatasvir, and sofosbuvir are approved, and SVR rates higher than 90% can be achieved. Especially for patients with a model of end stage liver disease score higher than 15 and therefore eligible for liver transplantation, data is scarce. Reported SVR rates in patients with cirrhosis CTP class C are lower compared to patients with a less severe liver disease. In liver transplant recipients with a maximum of CTP class A, SVR rates are comparable to patients without LT. Patients with decompensated graft cirrhosis should be treated on an individual basis.
Immunopathogenic mechanisms of autoimmune Hepatitis : how much do we know from animal models?
(2016)
Autoimmune hepatitis (AIH) is characterized by a progressive destruction of the liver parenchyma and a chronic fibrosis. The current treatment of autoimmune hepatitis is still largely dependent on the administration of corticosteroids and cytostatic drugs. For a long time the development of novel therapeutic strategies has been hampered by a lack of understanding the basic immunopathogenic mechanisms of AIH and the absence of valid animal models. However, in the past decade, knowledge from clinical observations in AIH patients and the development of innovative animal models have led to a situation where critical factors driving the disease have been identified and alternative treatments are being evaluated. Here we will review the insight on the immunopathogenesis of AIH as gained from clinical observation and from animal models.
Purpose: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carcinoma (mRCC).
Methods: A panel of experts convened to review currently available phase 3 data for mRCC treatment of approved agents, in addition to available EAU guideline data for a collaborative review as the plurality of substances offers different options of first-, second- and third-line treatment with potential sequencing.
Results: Sunitinib and pazopanib are approved treatments in first-line therapy for patients with favorable- or intermediate-risk clear cell RCC (ccRCC). Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with non-clear cell RCC (non-ccRCC). In the second-line treatment TKIs or mTOR inhibitors are treatment choices. Therapy options after TKI failure consist of everolimus and axitinib. Available third-line options consist of everolimus and sorafenib. Recently, nivolumab, a programmed death-1 (PD1) checkpoint inhibitor, improved overall survival benefit compared to everolimus after failure of one or two VEGFR-targeted therapies, which is likely to become the first established checkpoint inhibitor in mRCC. Data for the sequencing of agents remain limited.
Conclusions: Despite the high level of evidence for first and second-line treatment in mRCC, data for third-line therapy are limited. Possible sequences include TKI-mTOR-TKI or TKI–TKI-mTOR with the upcoming checkpoint inhibitors in perspective, which might settle a new standard of care after previous TKI therapy.
The CDK inhibitor SNS-032 had previously exerted promising anti-neuroblastoma activity via CDK7 and 9 inhibition. ABCB1 expression was identified as major determinant of SNS-032 resistance. Here, we investigated the role of ABCB1 in acquired SNS-032 resistance. In contrast to ABCB1-expressing UKF-NB-3 sub-lines resistant to other ABCB1 substrates, SNS-032-adapted UKF-NB-3 (UKF-NB-3rSNS- 032300nM) cells remained sensitive to the non-ABCB1 substrate cisplatin and were completely re-sensitized to cytotoxic ABCB1 substrates by ABCB1 inhibition. Moreover, UKF-NB-3rSNS-032300nM cells remained similarly sensitive to CDK7 and 9 inhibition as UKF-NB-3 cells. In contrast, SHEPrSNS-0322000nM, the SNS-032-resistant sub-line of the neuroblastoma cell line SHEP, displayed low level SNS-032 resistance also when ABCB1 was inhibited. This discrepancy may be explained by the higher SNS-032 concentrations that were used to establish SHEPrSNS-0322000nM cells, since SHEP cells intrinsically express ABCB1 and are less sensitive to SNS-032 (IC50 912 nM) than UKF-NB-3 cells (IC50 153 nM). In conclusion, we show that ABCB1 expression represents the primary (sometimes exclusive) resistance mechanism in neuroblastoma cells with acquired resistance to SNS-032. Thus, ABCB1 inhibitors may increase the SNS-032 efficacy in ABCB1-expressing cells and prolong or avoid resistance formation.
The Hepatitis C virus (HCV) infects more than 170 million individuals worldwide and causes challenging HCV-related diseases. Unfortunately, there is no vaccine available. Therefore, a better understanding of the HCV life cycle is urgently needed to develop more effective and better tolerated therapies.
It has been reported that the secretory pathway plays an essential role for the release of HCV, and the SNARE complexes are a central factor controlling intracellular vesicular trafficking. Recently, our group observed that α-taxilin that binds to free syntaxin 4 prevents the SNARE complex formation and exerts an inhibitory effect on the release of HCV particles. Therefore, it was analyzed whether the t-SNARE protein syntaxin 4 is involved in the HCV life cycle.
An increased intracellular amount of syntaxin 4 was found in HCV-positive cells, while the level of syntaxin 4-specific transcripts was decreased as observed in HCV-positive Huh7.5 cells and in HCV-infected primary human hepatocytes (PHH). Since in HCV-positive cells a significant longer half-life of syntaxin 4 was found, the decreased expression is overcompensated, leading to the elevated amount of syntaxin 4. Overexpression of syntaxin 4 increases the amount of secreted infectious viral particles, while silencing of syntaxin 4 expression decreases the number of released viral particles, which indicates that HCV could use the SNARE-dependent secretory pathway for viral release. Confocal immunofluorescence microscopy and co-immunoprecipitation experiments revealed that syntaxin 4 interacts with HCV core and NS5A. To identify the binding domain, various mutants of syntaxin 4 were generated. Based on these mutants, it was found that the H3 domain of syntaxin 4 interacts with core. These data show that the t-SNARE protein syntaxin 4 is an essential cellular factor for HCV morphogenesis and secretion.
HCV induces autophagy, and in HCV-infected cells a major fraction of the de novo synthesized viral particles is not released but intracellularly degraded. Syntaxin 17 is an autophagosomal SNARE required for the fusion of autophagosomes with lysosomes to form autolysosomes and thereby to deliver the enclosed contents for degradation. Therefore, we aim to investigate whether syntaxin 17 is a relevant factor for the HCV life cycle by regulating the fusion between autophagosomes and lysosomes. It was found that HCV-positive cells possess a decreased amount of syntaxin 17, and HCV reduces the intracellular level of syntaxin 17 by NS5A-mediated interruption of c-Raf signaling, which triggers the syntaxin 17 transcription, and by HCV-dependently induced autophagy. Overexpression of syntaxin 17 decreases the intracellular amount of viral particles and reduces the number of released infectious viral particles by favoring the formation of autolysosomes, in which HCV particles can be degraded. Vice versa, inhibition of syntaxin 17 expression by specific siRNAs results in an elevated amount of intracellular viral particles and increases the number of released viral particles by impaired autophagosome-lysosome fusion. Confocal immunofluorescence microscopy analyses show a fraction of core protein in autophagosomes as stained by lysotracker and the autophagy maker p62. These data identify syntaxin 17 as a novel factor controlling the release of HCV and reveal the autophagosome-autolysosome fusion as an essential step affecting the equilibrium between the release of infectious viral particles and lysosomal degradation of intracellular viral particles.
Taken together, these data identify the t-SNARE proteins syntaxin 4 and syntaxin 17 as essential cellular factors for HCV morphogenesis and secretion.
Prognostische Faktoren und das Outcome von Patienten mit einem primären Glioblastom sind in der Fachliteratur gut beschrieben. Im Gegensatz dazu gibt es wenige vergleichbare Informationen zu Patienten mit einem sekundären Glioblastom. Das Ziel dieser Arbeit war es, das Outcome von Patienten mit einem sekundären Glioblastom zu beurteilen und prognostische Faktoren in Be-zug auf das Gesamtüberleben zu identifizieren.
Dazu wurde die interne Datenbank des Universitätsklinikums Frankfurt/Main von Patienten mit Hirntumoren retrospektiv nach klinischen Daten durchsucht. Alle Patienten hatten ein histologisch gesichertes WHO Grad II oder III Gliom und anschließend ein WHO Grad IV sekundäres Glioblastom. Paraffiniertes Hirntumorgewebe wurde auf Mutationen der Isocitrat Dehydrogenase-1 (IDH1) mittels einer immunhistochemischen Färbung mit einem R132H (clone H09) spezifischen Antikörper untersucht. Eine uni- und multivariate statistische Analyse wurde durchgeführt, um Faktoren zu ermitteln, die potentiell das Gesamt-überleben beeinflussen könnten.
Es wurden 45 Patienten mit einem histologisch gesicherten sekundären Glioblastom untersucht. Das mediane Alter betrug 41 Jahre. 14 Patienten unterzogen sich einer radiologisch kompletten Resektion des sekundären Glioblastoms, 31 Patienten wurden subtotal reseziert oder biopsiert. Initial ist bei 37 Patienten ein astrozytärer Tumor nachgewiesen worden und die restlichen Patienten litten an Oligodendrogliomen oder gemischten Gliomen; bei der initialen Diagnose wurden 17 WHO Grad II und 28 WHO Grad III Tumoren fest-gestellt. Die mediane Zeit zwischen Ursprungstumor und dem Auftreten des sekundären Glioblastoms betrug 158,9 Wochen. Das mediane Gesamtüberleben betrug 445 Tage nach der Diagnose eines sekundären Glioblastoms. Mutationen des IDH1 (R132H) Proteins wurden bei 24 Patienten festgestellt und fehlten bei 17 Patienten; bei 4 Patienten konnte keine IDH1 immunhistochemische Färbung durchgeführt werden.
In der univariaten Analyse konnte der Zeitraum zwischen initialer Läsion und dem Progress zu einem sekundären Glioblastom als statistisch signifikanter Einflussfaktor identifiziert werden- Patienten mit einem Zeitraum von mehr als 2 Jahren hatten ein besseres Gesamtüberleben (460 vs. 327 Tage, p = 0,011). Außerdem konnte bei Patienten, die eine kombinierte Radiochemotherapie bekamen, ein besseres Gesamtüberleben nachgewiesen werden als bei Patienten, welche ausschließlich eine Therapieform erhielten (611 vs. 380 Tage, p < 0,001). Weiterhin konnten ein WHO Grad II Ursprungstumor (472 vs. 421 Tage, p = 0,05) und eine Frontalllappenlokalisation des Glioblastoms (472 vs. 425 Ta-ge, p = 0,031) das Überleben steigern.
In der multivariaten Analyse konnte gezeigt werden, dass die Mutation des IDH1 (R132H) Proteins in statistisch signifikanter Weise mit einem längeren Gesamtüberleben assoziiert war (p = 0,012); statistische Signifikanz für ein län-geres Gesamtüberleben bei Patienten mit initial einem WHO Grad II (p = 0,047) und einer Frontallappenlokalisation des Glioblastoms (p = 0,042) stellte sich auch ein. In Bezug auf die Patienten spezifischen Daten wurden zwei Prognosegruppen erstellt; Patienten in der guten Prognosegruppe scheinen einen Benefit von einer totalen Tumorresektion zu haben (p = 0,02), während eine Resektion für die andere Prognosegruppe keine große Rolle spielte (p = 0,926).
Trotz des relativ geringen Erkrankungsalters haben sekundäre Glioblastom Patienten eine schlechte Prognose. Die Ergebnisse dieser Arbeit unterstreichen die Wichtigkeit und den prognostischen Wert der IDH1 Diagnostik, die Notwendigkeit einer kombinierten Radiochemotherapie und eine Risikostratifizierung für eine Prognoseabschätzung anhand der Patienten spezifischen Einflussfaktoren.
Evidence about distribution patterns of brain metastases with regard to breast cancer subtypes and its influence on the prognosis of patients is insufficient. Clinical data, cranial computed tomography (CT) and magnetic resonance imaging (MRI) scans of 300 breast cancer patients with brain metastases (BMs) were collected retrospectively in four centers participating in the Brain Metastases in Breast Cancer Registry (BMBC) in Germany. Patients with positive estrogen (ER), progesterone (PR), or human epidermal growth factor receptor 2 (HER2) statuses, had a significantly lower number of BMs at diagnosis. Concerning the treatment mode, HER2-positive patients treated with trastuzumab before the diagnosis of BMs showed a lower number of intracranial metastases (p < 0.001). Patients with a HER2-positive tumor-subtype developed cerebellar metastases more often compared with HER2-negative patients (59.8% vs. 44.5%, p = 0.021), whereas patients with triple-negative primary tumors had leptomeningeal disease more often (31.4% vs. 18.3%, p = 0.038). The localization of Brain metastases (BMs) was associated with prognosis: patients with leptomeningeal disease had shorter survival compared with patients without signs of leptomeningeal disease (median survival 3 vs. 5 months, p = 0.025). A shorter survival could also be observed in the patients with metastases in the occipital lobe (median survival 3 vs. 5 months, p = 0.012). Our findings suggest a different tumor cell homing to different brain regions depending on subtype and treatment. View Full-Text
NOSTRIN belongs to the family of F-BAR proteins, which are multi-domain adaptor proteins that have emerged as important regulators of membrane remodeling and actin dynamics in a variety of vital cellular processes. They have been analyzed structurally and biochemically and overexpression studies have revealed their potential in inducing membrane curvature and tubulation. Several studies have begun to decipher the function of individual proteins, but the understanding of F-BAR protein functions in vivo is still quite limited. The F-BAR protein NOSTRIN is mainly expressed in endothelial cells and has originally been described as interaction partner of the endothelial nitric oxide synthase (eNOS), modulating eNOS subcellular localization. The phenotypic characterization of NOSTRIN knockout mice revealed decreased nitric oxide (NO) and cGMP levels, an increase in systolic blood pressure and an impairment of the acetylcholine-induced, NO-dependent relaxation of aortic rings from mice with global as well as endothelial cell-specific knockout of the NOSTRIN gene (ECKO) . These findings implied that NOSTRIN plays a role in regulating NO production in vivo, but the underlying molecular mechanisms were unclear. Therefore, this study was aimed at addressing the mechanism causing the inhibited vasodilation specifically upon stimulation with acetylcholine in NOSTRIN KO and ECKO mice, and at exploring additional roles of NOSTRIN in the signal transduction of endothelial cells.
The major acetylcholine receptor that mediates vessel relaxation upon stimulation with acetylcholine is the muscarinic acetylcholine receptor subtype M3 (M3R). In the present study NOSTRIN was identified as novel interaction partner of the M3R and important factor for the correct spatial distribution and functionality of the M3R. Moreover, it provides the first example of an F-BAR protein regulating a GPCR. Confocal immunofluorescence microscopy analysis of isolated aortae from NOSTRIN KO and WT mice indicated that NOSTRIN was necessary for the proper subcellular localization of the M3R and targeted it to the plasma membrane. A series of pulldown experiments revealed a direct interaction of NOSTRIN with the M3R. The binding required the SH3 domain of NOSTRIN and the third intracellular loop of the M3R, which has a recognized role in receptor regulation. The interaction of NOSTRIN with the M3R was confirmed by co-localization of NOSTRIN and the M3R upon overexpression in mammalian cells. Expression levels of the M3R as well as eNOS were not affected by the loss of NOSTRIN in accordance with the finding, that NOSTRIN impacts on the acetylcholine/eNOS signaling axis through regulation of the subcellular trafficking of its binding partners.
Furthermore, there were first indications for a role of NOSTRIN in facilitating the carbachol-induced calcium response in M3R-expressing cells, suggesting that NOSTRIN might influence M3R activation. in the absence of NOSTRIN, the function of the M3R in mammalian cells overexpressing the M3R was markedly impaired, resulting in abolition of the calcium response to the M3R agonist carbachol. In accordance, the activated eNOS fraction associated with the Golgi complex was markedly reduced in aorta explants from NOSTRIN knockout and ECKO mice. Moreover, NOSTRIN knockout inhibited the carbachol-induced, activating phosphorylation of eNOS in murine aortae as well as primary mouse lung endothelial cells confirming its role as important regulator of eNOS activity in vivo.
Purpose: A study of real-time adaptive radiotherapy systems was performed to test the hypothesis that, across delivery systems and institutions, the dosimetric accuracy is improved with adaptive treatments over non-adaptive radiotherapy in the presence of patient-measured tumor motion.
Methods and materials: Ten institutions with robotic(2), gimbaled(2), MLC(4) or couch tracking(2) used common materials including CT and structure sets, motion traces and planning protocols to create a lung and a prostate plan. For each motion trace, the plan was delivered twice to a moving dosimeter; with and without real-time adaptation. Each measurement was compared to a static measurement and the percentage of failed points for γ-tests recorded.
Results: For all lung traces all measurement sets show improved dose accuracy with a mean 2%/2 mm γ-fail rate of 1.6% with adaptation and 15.2% without adaptation (p < 0.001). For all prostate the mean 2%/2 mm γ-fail rate was 1.4% with adaptation and 17.3% without adaptation (p < 0.001). The difference between the four systems was small with an average 2%/2 mm γ-fail rate of <3% for all systems with adaptation for lung and prostate.
Conclusions: The investigated systems all accounted for realistic tumor motion accurately and performed to a similar high standard, with real-time adaptation significantly outperforming non-adaptive delivery methods.
BACKGROUND: Polyclonal anti-thymocyte globulins (ATGs) are immunosuppressive drugs widely used in induction of immunosuppression and treatment of acute rejection after solid organ transplantation. We have previously demonstrated that ATGs bind to endothelial cells in vitro, and are able to modulate ECs. The aim of this study was to investigate the binding of ATGs to endothelial cells under in vivo conditions.
MATERIAL AND METHODS: Muscle biopsies from extremities of cynomolgus monkeys were obtained after ischemia/reperfusion at 4°C. ATGs (Thymoglobulin, Sanofi-Aventis, France; 1 mg/kg) were added to the blood 30 min prior to the reperfusion. Biopsies (n=10) of patients undergoing heart transplantation and preoperatively treated with ATGs (Thymoglobulin, Sanofi-Aventis, France; 1.5 mg/kg) as induction therapy were also analyzed 6 hours and 7 days after induction. Binding of ATGs to ECs was analyzed with an anti-rabbit IgG antibody by means of immunohistochemistry.
RESULTS: Binding of ATGs to endothelial cells could be demonstrated in vivo in our animal experiments 4 hours after reperfusion, as well as in the clinical biopsies 6 hours after induction of immunosuppression in heart transplant patients, showing a preferred localization in post-capillary veins. No expression of ATGs on the endothelial surface could be observed after 7 days, suggesting that ATGs may be washed out from the endothelial surface in a time-dependent manner.
CONCLUSIONS: Our results show that ATGs are able to bind to endothelial cells in an experimental model and in clinical practice, supporting preconditioning strategies with ATGs in solid organ transplantation.
Introduction: In the time of increasing resistance and paucity of new drug development there is a growing need for strategies to enhance rational use of antibiotics in German and Austrian hospitals. An evidence-based guideline on recommendations for implementation of antibiotic stewardship (ABS) programmes was developed by the German Society for Infectious Diseases in association with the following societies, associations and institutions: German Society of Hospital Pharmacists, German Society for Hygiene and Microbiology, Paul Ehrlich Society for Chemotherapy, The Austrian Association of Hospital Pharmacists, Austrian Society for Infectious Diseases and Tropical Medicine, Austrian Society for Antimicrobial Chemotherapy, Robert Koch Institute.
Materials and methods: A structured literature research was performed in the databases EMBASE, BIOSIS, MEDLINE and The Cochrane Library from January 2006 to November 2010 with an update to April 2012 (MEDLINE and The Cochrane Library). The grading of recommendations in relation to their evidence is according to the AWMF Guidance Manual and Rules for Guideline Development.
Conclusion: The guideline provides the grounds for rational use of antibiotics in hospital to counteract antimicrobial resistance and to improve the quality of care of patients with infections by maximising clinical outcomes while minimising toxicity. Requirements for a successful implementation of ABS programmes as well as core and supplemental ABS strategies are outlined. The German version of the guideline was published by the German Association of the Scientific Medical Societies (AWMF) in December 2013.
Background: Infection is a main cause of morbidity and mortality after heart surgery, with multi-resistant pathogens increasingly representing a challenge. Daptomycin provides bactericidal activity against gram-positive organisms that are resistant to standard treatment including vancomycin.
Methods: A cohort of cardiac surgical patients, treated with daptomycin for major infection at two tertiary care centers, were retrospectively studied with a particular focus on the type of infection, causative pathogens and co-infections, daptomycin dosage, adverse events and outcome in order to provide evidence for the efficiency and safety of daptomycin in a distinct high-risk patient population.
Results: Sixty-five patients (87.7 % males, 60.4 ± 13.5 years) who had undergone aortic surgery (20.0 %), ventricular assist device (VAD) implantation (21.5 %), combined procedures (21.5 %), coronary artery bypass grafting (12.3 %), isolated valve surgery (15.4 %) and heart transplantation (7.7 %) were diagnosed with catheter-related infection (26.1 %), valve endocarditis (18.8 %), sternal wound (13.0 %), VAD-associated (11.6 %), cardiac implantable electrophysiological device (CIED)-associated (4.1 %), respiratory tract (4.3 %), bloodstream (4.3 %) and other infection (4.3 %). In 13.0 %, no focus of infection was identified though symptoms of severe infection were present. The most frequent pathogens were Staphylococcus epidermidis (30.4 %), Staphylococcus aureus (23.1 %) and Enterococcus species (10.1 %). Daptomycin doses ranging from 3 mg/kg every 48 h to 10 mg/kg every 24 h were administered for 15.4 ± 11.8 days. 87.0 % of the cases were classified as success, 7.2 % as treatment failure and 5.8 as non-evaluable. Adverse events were limited to one case of mild and one case of moderate neutropenia with recovery upon termination of treatment.
Conclusion: Daptomycin proved safe and effective in major infection in high-risk cardiac surgical patients.
Expression of kidney injury molecule-1 (Kim-1) is rapidly upregulated following tubular injury, constituting a biomarker for acute kidney damage. We examined the renal localization of Kim-1 expression in PKD/Mhm (polycystic kidney disease, Mannheim) (cy/+) rats (cy: mutated allel, +: wild type allel), an established model for autosomal dominant polycystic kidney disease, with chronic, mainly proximal tubulointerstitial alterations. For immunohistochemistry or Western blot analysis, kidneys of male adult heterozygously-affected (cy/+) and unaffected (+/+) littermates were perfusion-fixed or directly removed. Kim-1 expression was determined using peroxidase- or fluorescence-linked immunohistochemistry (alone or in combination with markers for tubule segments or differentiation). Compared to (+/+), only in (cy/+) kidneys, a chronic expression of Kim-1 could be detected by Western blot analysis, which was histologically confined to an apical cellular localization in areas of cystically-transformed proximal tubules with varying size and morphology, but not in distal tubular segments. Kim-1 was expressed by cystic epithelia exhibiting varying extents of dedifferentiation, as shown by double labeling with aquaporin-1, vimentin or osteopontin, yielding partial cellular coexpression. In this model, in contrast to other known molecules indicating renal injury and/or repair mechanisms, the chronic renal expression of Kim-1 is strictly confined to proximal cysts. Its exact role in interfering with tubulo-interstitial alterations in polycystic kidney disease warrants future investigations.
Background: Long noncoding RNAs (lncRNAs) are non-protein coding transcripts regulating a variety of physiological and pathological functions. However, their implication in heart failure is still largely unknown. The aim of this study is to identify and characterize lncRNAs deregulated in patients affected by ischemic heart failure.
Methods: LncRNAs were profiled and validated in left ventricle biopsies of 18 patients affected by non end-stage dilated ischemic cardiomyopathy and 17 matched controls. Further validations were performed in left ventricle samples derived from explanted hearts of end-stage heart failure patients and in a mouse model of cardiac hypertrophy, obtained by transverse aortic constriction. Peripheral blood mononuclear cells of heart failure patients were also analyzed. LncRNA distribution in the heart was assessed by in situ hybridization. Function of the deregulated lncRNA was explored analyzing the expression of the neighbor mRNAs and by gene ontology analysis of the correlating coding transcripts.
Results: Fourteen lncRNAs were significantly modulated in non end-stage heart failure patients, identifying a heart failure lncRNA signature. Nine of these lncRNAs (CDKN2B-AS1/ANRIL, EGOT, H19, HOTAIR, LOC285194/TUSC7, RMRP, RNY5, SOX2-OT and SRA1) were also confirmed in end-stage failing hearts. Intriguingly, among the conserved lncRNAs, h19, rmrp and hotair were also induced in a mouse model of heart hypertrophy. CDKN2B-AS1/ANRIL, HOTAIR and LOC285194/TUSC7 showed similar modulation in peripheral blood mononuclear cells and heart tissue, suggesting a potential role as disease biomarkers. Interestingly, RMRP displayed a ubiquitous nuclear distribution, while H19 RNA was more abundant in blood vessels and was both cytoplasmic and nuclear. Gene ontology analysis of the mRNAs displaying a significant correlation in expression with heart failure lncRNAs identified numerous pathways and functions involved in heart failure progression.
Conclusions: These data strongly suggest lncRNA implication in the molecular mechanisms underpinning HF.
Long noncoding RNAs (lncRNAs) are non-protein coding RNAs regulating gene expression. Although for some lncRNAs a relevant role in hypoxic endothelium has been shown, the regulation and function of lncRNAs is still largely unknown in the vascular physio-pathology. Taking advantage of next-generation sequencing techniques, transcriptomic changes induced by endothelial cell exposure to hypoxia were investigated. Paired-end sequencing of polyadenylated RNA derived from human umbilical vein endothelial cells (HUVECs) exposed to 1% O2 or normoxia was performed. Bioinformatics analysis identified ≈2000 differentially expressed genes, including 122 lncRNAs. Extensive validation was performed by both microarray and qPCR. Among the validated lncRNAs, H19, MIR210HG, MEG9, MALAT1 and MIR22HG were also induced in a mouse model of hindlimb ischemia. To test the functional relevance of lncRNAs in endothelial cells, knockdown of H19 expression was performed. H19 inhibition decreased HUVEC growth, inducing their accumulation in G1 phase of the cell cycle; accordingly, p21 (CDKN1A) expression was increased. Additionally, H19 knockdown also diminished HUVEC ability to form capillary like structures when plated on matrigel. In conclusion, a high-confidence signature of lncRNAs modulated by hypoxia in HUVEC was identified and a significant impact of H19 lncRNA was shown.
Measles virus (MeV) is an aerosol-borne and one of the most contagious pathogenic viruses known. Almost every MeV infection becomes clinically manifest and can lead to serious and even fatal complications, especially under conditions of malnutrition in developing countries, where still 115,000 to 160,000 patients die from measles every year. There is no specific antiviral treatment. In addition, MeV infections cause long-lasting memory B and T cell impairment, predisposing people susceptible to opportunistic infections for years. A rare, but fatal long-term consequence of measles is subacute sclerosing panencephalitis. Fifteen years ago (2001), WHO has launched a programme to eliminate measles by a worldwide vaccination strategy. This is promising, because MeV is a human-specific morbillivirus (i.e. without relevant animal reservoir), safe and potent vaccine viruses are sufficiently produced since decades for common application, and millions of vaccine doses have been used globally without any indications of safety and efficacy issues. Though the prevalence of wild-type MeV infection has decreased by >90 % in Europe, measles is still not eliminated and has even re-emerged with recurrent outbreaks in developed countries, in which effective vaccination programmes had been installed for decades. Here, we discuss the crucial factors for a worldwide elimination of MeV: (1) efficacy of current vaccines, (2) the extremely high contagiosity of MeV demanding a >95 % vaccination rate based on two doses to avoid primary vaccine failure as well as the installation of catch-up vaccination programmes to fill immunity gaps and to achieve herd immunity, (3) the implications of sporadic cases of secondary vaccine failure, (4) organisation, acceptance and drawbacks of modern vaccination campaigns, (5) waning public attention to measles, but increasing concerns from vaccine-associated adverse reactions in societies with high socio-economic standards and (6) clinical, epidemiological and virological surveillance by the use of modern laboratory diagnostics and reporting systems. By consequent implementation of carefully designed epidemiologic and prophylactic measures, it should be possible to eradicate MeV globally out of mankind, as the closely related morbillivirus of rinderpest could be successfully eliminated out of the cattle on a global scale.
Background: Establishing a strong link early on between preclinical coursework and the clinical context is necessary for students to be able to recognize the practical relevance of the curriculum during their preclinical anatomical courses and to transfer knowledge more easily. Our objective was to enhance the clinical relevance of a preclinical anatomy course for second-year medical students of dentistry by implementing an interdisciplinary skills training course on "Palpation of the Head and Neck Muscles" and to measure the learning outcomes.
Methods: For the curricular development of the expanded course module, Kern’s 6-step approach was applied including subjective evaluation. We used a peer-teaching format supported by an e-learning application. A randomized control study measured effects of the two components (skills training, e-module) on learning outcomes. Four learning methods were compared: (1) lecture, (2) lecture + e-module, (3) lecture + skills training, (4) lecture + skills training + e-module. An objective structured clinical examination (OSCE) was used to measure and compare learning outcomes.
Results: The two-way variance analysis demonstrated that participation in the skills training had a statistically significant effect on the OSCE results (p = 0.0007). Students who participated in the skills training did better (φ 107.4 ± 14.4 points) than students who only attended the lecture (φ 88.8 ± 26.2 points). Students who used the e-module but did not attend the skills training earned a slightly but not significantly higher average number of points (φ 91.8 ± 31.3 points) than those who only attended the lecture. The learning outcomes of the skills training were again significantly increased when the training was combined with the e-module (φ 121.8 ± 21.8 points), thus making it the ideal method for achieving the learning objectives defined in this study.
Conclusions: The "Palpation of the Head and Neck Muscles" interdisciplinary skills training course linking basic anatomical knowledge and clinical skills led to clearly improved learning outcomes for both, anatomical knowledge and clinical skills. The additional use of an e-learning tool (e-module) improved the learning effect.
Das idiopathische Parkinsonsyndrom (IPS) wurde durch James Parkinson im Jahr 18171 vornehmlich als neurologische Bewegungsstörung beschrieben. Durch die Verdienste umfassender Forschung und klinischer Diagnostik der letzten Jahrzehnte wird das IPS heute als Syndrom aufgefasst, das neben motorischen auch durch neuropsychiatrische, vegetative und sensible Symptome charakterisiert ist. Eines dieser sogenannten „nicht-motorischen Symptome“ bildet die (milde) kognitive Beeinträchtigung, die jeden vierten nicht-dementen Parkinsonpatienten betrifft2 und die im oft langjährigen Krankheitsverlauf in eine Parkinsondemenz münden kann, an der 8 Jahre nach Krankheitsbeginn bis zu 78% der Parkinsonpatienten leiden.3 Durch die steigende Lebenserwartung der Patienten und die besseren Therapieoptionen der motorischen Komponente eines IPS finden derzeit gerade die nicht-motorischen Symptome sowohl in der Forschung als auch der Klinik zunehmend stärkere Beachtung.
Die motorische Symptomatik des IPS wird vorrangig durch die Degeneration dopaminerger Neuronen in bestimmten Strukturen des Hirnstamms hervorgerufen.4 Die Entwicklung kognitiver Symptome ist komplexer und umfasst vermutlich neben der (genannten) dopaminergen Degeneration die Beeinträchtigung weiterer Neurotransmitter sowie degenerative Prozesse an anderer Stelle des ZNS.5 Insbesondere die Atrophie von frontalem, parietalem und (medio-) temporalem Cortex scheint mit der Parkinsondemenz assoziiert.6–8 Auch gleichzeitig auftretende histopathologische Prozesse, die für die Alzheimer-Demenz charakteristisch sind, werden diskutiert.9
Der Hippocampus, eine Struktur des Mediotemporallappens, leistet einen bedeutenden Beitrag zum deklarativen räumlichen Gedächtnis und zum Arbeitsgedächtnis sowie zur Verarbeitung von Emotionen, sodass er beim normalen Altern, aber auch vielen Erkrankungen, eine wichtige Rolle einnimmt.10–12 Vor allem bei der Alzheimer-Demenz ist der Hippocampus eine sehr früh von der Atrophie betroffene Struktur.13 In den letzten Jahren mehren sich die Hinweise, dass dies auch bei der Parkinsondemenz der Fall ist.14–16 Aus diesem Grund wird im Folgenden ein besonderes Augenmerk auf diese Struktur gelegt.
Die vorliegende Studie setzt sich mit der Fragestellung auseinander, ob und inwiefern sich Parkinsonpatienten mit unterschiedlich ausgeprägten kognitiven Einschränkungen in den Volumina ausgewählter Hirnstrukturen – darunter die corticale graue und weiße 8 Substanz, der Hippocampus und die Hirnventrikel – sowie in den neuropsychologischen Domänen Gedächtnis, Exekutivfunktionen und Aufmerksamkeit, Sprache und visuell-räumliche Funktionen unterscheiden. Außerdem wird untersucht, ob zwischen den Hirnvolumina und dem Grad der kognitiven Einschränkung ein Zusammenhang besteht. Hierzu werden Parkinsonpatienten ohne Demenz (PD), Parkinsonpatienten mit milder kognitiver Beeinträchtigung (PD-MCI) und Patienten mit Parkinsondemenz (PDD) neuropsychologisch untersucht und magnetresonanztomographische Aufnahmen des Gehirns erstellt. Die mit einem automatisierten Messprogramm ermittelten Hirnvolumina werden in Korrelation zu Testungen des Gedächtnisses, der Exekutive und Aufmerksamkeit, der Sprache und visuell-räumlicher Funktionen gesetzt.
Die Arbeit gliedert sich wie folgt: Zum besseren Verständnis der kognitiven Symptomatik werden im ersten Kapitel die nicht-kognitiven Symptome des IPS charakterisiert sowie der aktuelle Wissensstand über Kognition beim IPS wiedergegeben. Anschließend werden die technischen Grundlagen der Magnetresonanztomographie und Methoden zur Auswertung struktureller MRT-Bilder erläutert. Darauf aufbauend wird die Fragestellung konkretisiert, bevor im zweiten Teil der Arbeit die Vorstellung des Studiendesigns, die Präsentation der Ergebnisse und im letzten Teil die Diskussion erfolgen.
Herb induced liver injury (HILI) and drug induced liver injury (DILI) share the common characteristic of chemical compounds as their causative agents, which were either produced by the plant or synthetic processes. Both, natural and synthetic chemicals are foreign products to the body and need metabolic degradation to be eliminated. During this process, hepatotoxic metabolites may be generated causing liver injury in susceptible patients. There is uncertainty, whether risk factors such as high lipophilicity or high daily and cumulative doses play a pathogenetic role for HILI, as these are under discussion for DILI. It is also often unclear, whether a HILI case has an idiosyncratic or an intrinsic background. Treatment with herbs of Western medicine or traditional Chinese medicine (TCM) rarely causes elevated liver tests (LT). However, HILI can develop to acute liver failure requiring liver transplantation in single cases. HILI is a diagnosis of exclusion, because clinical features of HILI are not specific as they are also found in many other liver diseases unrelated to herbal use. In strikingly increased liver tests signifying severe liver injury, herbal use has to be stopped. To establish HILI as the cause of liver damage, RUCAM (Roussel Uclaf Causality Assessment Method) is a useful tool. Diagnostic problems may emerge when alternative causes were not carefully excluded and the correct therapy is withheld. Future strategies should focus on RUCAM based causality assessment in suspected HILI cases and more regulatory efforts to provide all herbal medicines and herbal dietary supplements used as medicine with strict regulatory surveillance, considering them as herbal drugs and ascertaining an appropriate risk benefit balance.
The most frequently used parameters to describe the barrier properties of endothelial cells (ECs) in vitro are (i) the macromolecular permeability, indicating the flux of a macromolecular tracer across the endothelium, and (ii) electrical impedance of ECs grown on gold-film electrodes reporting on the cell layer's tightness for ion flow. Due to the experimental differences between these approaches, inconsistent observations have been described. Here, we present the first direct comparison of these assays applied to one single cell type (human microvascular ECs) under the same experimental conditions. The impact of different pharmacological tools (histamine, forskolin, Y-27632, blebbistatin, TRAP) on endothelial barrier function was analyzed by Transwell(®) tracer assays and two commercial impedance devices (xCELLigence(®), ECIS(®)). The two impedance techniques provided very similar results for all compounds, whereas macromolecular permeability readings were found to be partly inconsistent with impedance. Possible reasons for these discrepancies are discussed. We conclude that the complementary combination of both approaches is highly recommended to overcome the restrictions of each assay. Since the nature of the growth support may contribute to the observed differences, structure-function relationships should be based on cells that are consistently grown on either permeable or impermeable growth supports in all experiments.
Positive Effekte körperliche Aktivität als komplementäre Therapie in der Onkologie wurden in den letzten Jahren in zahlreichen Studien aufgezeigt. Hierbei zeigte sich ein Anstieg der körperlichen Fitness und Muskelmasse, eine Steigerung der Lebensqualität, eine Reduktion des Fatigue-Syndroms, aber auch eine verbesserte Therapieverträglichkeit sowie einer Rezidiv-Prophylaxe (Backman et al., 2014; Meyerhardt et al., 2006; Segal et al., 2001). Daraufhin wurden Empfehlungen für körperliche Aktivität im Rahmen der onkologischen Therapie ausgesprochen, welche 150 Minuten moderate körperliche Aktivität pro Woche umfassen. Diese Empfehlungen basieren auf entitätsunspezifische Studienkollektive mit meist Tumorstadium I und II. Eine Vielzahl an Studien verdeutlichen, dass gerade Patienten in fortgeschrittenen Tumorstadien mit zahlreichen therapie- sowie tumorbedingten Nebenwirkungen zu kämpfen haben und dadurch ein stärkerer Abbau der körperlichen Fitness, der Muskulatur, aber auch der funktionellen Eigenschaften vorzufinden ist. Hierbei stellen Patienten mit fortgeschrittenen gastrointestinalen Tumoren (GIT) ein stark belastetes Kollektiv dar, da 80 Prozent dieser Patienten eine Tumorkachexie erleiden. Zusätzliche wurde in einer Querschnittsuntersuchung aufgezeigt, dass Patienten mit fortgeschrittenen GIT bereits vor Therapiestart einen deutlich verminderten körperlichen und funktionellen Status im Vergleich zu Mammakarzinom-Patientinnen und Gesunden aufweisen (Stuecher et al., 2016). In der vorliegenden randomisiert kontrollierten Untersuchung wurde erstmals ein heimbasiertes Training ohne Supervision zur Steigerung der körperlichen Aktivität bei Patienten mit fortgeschrittenen GIT durchgeführt und dieses mit einer leitliniengetreuen onkologischen Therapie ohne komplementäre Bewegungstherapie verglichen. Dabei wurden der körperliche und funktionelle Status sowie die Aktivitäten des täglichen Lebens verglichen.
Zweiundvierzig Patienten mit fortgeschrittenen GIT (UICC ≥ III, 67,1 ± 6,8 Jahre, 45,2 % weiblich) wurden vor ihrer geplanten first-line Chemotherapie (CT) in die zweiarmige randomisiert kontrollierte Studie eingeschlossen. Eine der Gruppen (I) erhielt, entsprechend der ACSM-Guidelines für onkologische Patienten, die Vorgabe ein wöchentliches Laufprogramm mit einem Umfang von 150 Minuten moderater Intensität pro Woche. Die zweite Gruppe diente als Kontrollgruppe (K) und erhielt am Ende der Studiendauer entsprechende Empfehlungen. Die Interventionsdurchführung wurde mittels Trainingstagebuch und Pedometer begleitet. Vor Beginn (T0), nach zwei CT-zyklen (T1) sowie nach zwölf Wochen (T2) wurde der funktionelle und körperliche Status sowie die Alltagsbewältigung der Patienten erfasst.
Bei einer Dropoutrate von 36 Prozent konnten 28 (K: 15; I; 13) Patienten die Studie komplett durchlaufen. Die mittlere Adhärenzrate lag bei 81,3 Prozent. Im Untersuchungszeitraum konnten die folgenden sign. Veränderungen (p< 0,05) der einzelnen Parameter gezeigt werden. Die posturale Stabilität (COPLänge) konnte sowohl ein Gruppeneffekt, als auch ein Zeiteffekt nachgewiesen werden. Die Interventionsgruppe verbesserte sich im Zeitraum T0-T1 (-71,47mm) sowie im Gesamtzeitraum T0-T2 (-74,13 mm), wohingegen die Kontrollgruppe sich im Gesamtzeitraum T0-T2 (+72,83) verschlechterte. Die Gruppen unterschieden sich daher sowohl in den Zeiträumen T0-T1 ((K)+38,61; (I)-71,47 mm) sowie T0-T2 ((K)+72,83; (I) -74,13mm). Bezüglich des körperlichen Status konnte sich die Interventionsgruppe von T1-T2 (+4,03 kg) sowie von T0-T2 (+4,04 kg) verbessern, sodass sich die Gruppen zwischen den Zeitpunkten T1-T2 ((K) -0,49; (I)+4,03 kg) und T0-T2 ((K) 0,19; 4,04 kg) unterschieden. Der iADL-Fragebogen erbrachte eine Verbesserung der Interventionsgruppe im Gesamtmesszeitraum T0-T2 (+0,12), daraus resultierte ein zusätzlicher Gruppenunterschied in diesem Zeitraum ((K) -0,89; (I) +0,12). Der Ernährungszustand zeigte auch einen unterschiedlichen Verlauf der beiden Gruppen. Zwischen T1-T2 ((K) -0,59; + 1,74) sowie T0-T2 ((K) -0,55; (I) +2,39) unterschieden sich die Gruppen.
Obgleich es für einige Patienten schwierig war die Laufintervention gemäß den Empfehlungen durchzuführen, weisen die Teilnehmer der Interventionsgruppe sowohl in den Parametern des körperlichen, als auch des funktionellen Status Verbesserungen auf. Demnach scheint ein durchschnittlicher Umfang von zwei Stunden moderater körperlicher Aktivität während einer Tumortherapie ausreichend zu sein. Es veranschaulicht, dass eine komplementäre Bewegungstherapie in der onkologischen Therapie bei Patienten mit fortgeschrittenen GIT sinnvoll ist und sowohl einen Benefit in der Körperzusammensetzung, als auch der funktionellen Eigenschaften mitsichbringt. Dies hat wiederum einen positiven Einfluss auf die Alltagsbewältigung. Da einige Barrieren das Laufprogramm der Patienten einschränkten oder gar zum Laufabbruch führten, sollte versucht werden diese zu mindern. Hierbei sind vor allem klima- und wetterbedingte Barrieren ein möglicher Ansatzpunkt, da Nebenwirkungen kaum vermeidbar sind. Dennoch sollten die Patienten auch nach nebenwirkungsbedingten Laufpausen motiviert werden das Programm weiterzuführen. Diese Studie gibt zudem erste Hinweise, dass durch eine komplementäre Bewegungstherapie mit moderater körperlicher Aktivität die Toxizität der CT bei Patienten mit fortgeschrittenen GIT vermindert werden kann. Da der klinische Benefit, welcher in einigen Studien anderer Tumorentitäten postuliert wurde, in dieser Untersuchung nicht objektiv erfasst wurde, wäre dies ein möglicher Ansatzpunkt für Folgestudien.
Hintergrund: Die Delegation ärztlicher Leistungen an nichtärztliches medizinisches Fachpersonal wird in Deutschland vor dem Hintergrund eines absehbaren Hausärztemangels bei gleichzeitig wachsendem Bedarf an hausärztlichen Betreuungsleistungen seit einiger Zeit diskutiert. Inzwischen wurden unterschiedliche Qualifikationsmodelle für Medizinische Fachangestellte (MFA) (z.B. die Versorgungs-assistentin in der Hausarztpraxis, VERAH) konzipiert und implementiert, die für eine Delegation von Leistungen qualifizieren. VERAH sind v.a. in Baden-Württemberg in Hausarztpraxen tätig, da deren Einsatz dort im Rahmen der Hausarztzentrierten Versorgung (HzV) seit 2008 finanziell honoriert wird. Dabei ist es den Praxen freigestellt, wie sie das VERAH-Konzept und damit auch die Delegation umsetzen. Auch gesetzliche Vorgaben zur Delegation lassen erheblichen Spielraum bei der Umsetzung. Erschwerend kommt hinzu, dass weiterhin Unklarheit darüber besteht, welche Leistungsübertragung als „Delegation“ und welche eher als „Substitution“ zu verstehen ist.
Zielrichtung der Arbeit: Ziel dieser publikationsbasierten Dissertation ist eine Darstellung der Formen und Graduierungen von Delegation, d.h. der tatsächlichen Umsetzung von Leistungsübertragung in der Hausarztpraxis am Beispiel der VERAH in Baden-Württemberg. Es können Empfehlungen für das Gelingen der Delegation aus der Analyse von Ergebnissen auf Patienten-, Praxis- und Teamebene abgeleitet werden.
Resultate: Diese Dissertation basiert auf sechs Publikationen, die im Rahmen von zwei Projekten zur Evaluation des VERAH-Einsatzes in der HzV in Baden-Württemberg entstanden. Die Evaluationen basieren auf einem Mixed Methods-Design, d.h. auf der Analyse von querschnittlich erhobenen quantitativen Daten sowie qualitativen Daten zu verschiedenen Fragen des VERAH-Einsatzes.
Es existiert ein breites Spektrum an Formen und Graduierungen der Delegation in Hausarztpraxen, die am HzV-Modell teilnehmen. VERAH übernehmen einerseits supplementäre (zusätzliche) ärztliche Tätigkeiten, wie z.B. Geriatrisches Assessment oder Impfberatungen, aber auch komplementäre (ergänzende) Tätigkeiten wie z.B. die Beratung der Angehörigen zu Hilfeleistungen im Gesundheitssystem. Vor allem im Rahmen von Hausbesuchen üben VERAH auch substituierende (ersetzende) Funktionen
aus. Auf Patientenseite sind gerade ältere, multimorbide und pflegebedürftige Patienten Empfänger delegierter Leistungen. Sie erhalten eine umfassende Betreuung und werden beim Erhalt ihrer häuslichen Selbständigkeit unterstützt. Die Patienten sehen in der VERAH eine zusätzliche Vertrauensperson in der Praxis und akzeptieren sie als kompetente Ansprechpartnerin. Die Hausärzte profitieren durch die Delegation von Tätigkeiten an VERAH, indem sie entlastet werden und Zeit für wichtige medizinische Aufgaben gewinnen. Für VERAH stellt die Delegation eine Erweiterung ihrer Tätigkeits- und Kompetenzbereiche dar und kann insofern als ein Schritt zur Professionalisierung des nichtärztlichen Personals einer Hausarztpraxis gelten.
Viele Faktoren, die zum Gelingen einer Umsetzung der Delegation beitragen, können vom hausärztlichen Team selbst beeinflusst werden. Darunter fallen das Engagement der MFA, die Qualifikation, zeitliche Flexibilität, ausreichend Gestaltungsspielraum, Grad der Autonomie, Abgrenzung des Verantwortungsbereiches und auch adäquates Equipment. Entsprechend richten sich die hier formulierten Empfehlungen meist an die Praxis, aber auch an den Gesetzgeber.
Bedeutung für die übergeordnete Fragestellung: Die Ergebnisse dieser Arbeit zeigen, dass mit dem VERAH-Konzept erste Ansätze einer teambasierten Versorgung vorhanden sind, und dass sich die Analyse dieses Konzeptes eignet, um Desiderata für die Zukunft von Delegation (haus-)ärztlicher Leistungen an nichtärztliches Personal formulieren zu können. Teambasierte Ansätze bedürfen, wie auch internationale Beispiele verdeutlichen, einer Weiterentwicklung der bestehenden Delegationskonzepte in deutschen Hausarztpraxen. Idealerweise mündet eine mit Delegation einhergehende Aufgaben- und Rollenneuverteilung in einer Betreuungsform, in der alle Teammitglieder entsprechend ihrer Qualifikation an der Versorgung der Patienten in der Hausarztpraxis beteiligt sind. Daher kommt die Einbindung von Pflegekräften in die hausärztliche Versorgung genauso in Frage, wie auch speziell ausgebildete VERAH/MFA. In jedem Fall sollte über Schritte der Professionalisierung nichtärztlicher Berufsgruppen nachgedacht werden. Ob sich in Deutschland, wie in den USA und in Kanada, aus diesen Delegationskonzepten im Laufe der Zeit Substitution (im Sinne der Verantwortungsübertragung an nichtärztliche Berufsgruppen) entwickelt, bleibt abzuwarten. Die Ergebnisse der Dissertation zeigen, dass es mit der gegenwärtigen Umsetzung der Delegation an VERAH zu einer Erweiterung des Leistungsspektrums in den Hausarztpraxen kommen kann; eine Ausweitung der Delegation sollte jedoch zeitnah vorangetrieben werden.